WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: C07D 239/26, C09K 19/34

(11) International Publication Number:

WO 99/33814

(43) International Publication Date:

8 July 1999 (08.07.99)

(21) International Application Number:

PCT/US98/14624

A1

(22) International Filing Date:

15 July 1998 (15.07.98)

(30) Priority Data:

08/998,400

24 December 1997 (24.12.97) US

(71) Applicant: MINNESOTA MINING AND MANUFACTUR-ING COMPANY [US/US]; 3M Center, P.O. Box 33427, Saint Paul, MN 55133-3427 (US).

(72) Inventors: HASEGAWA, Masakazu; P.O. Box 33427, Saint Paul, MN 55133-3427 (US). KEYES, Michael, P.; P.O. Box 33427, Saint Paul, MN 55133-3427 (US). RAD-CLIFFE, Marc, D.; P.O. Box 33427, Saint Paul, MN 55133-3427 (US). SAVU, Patricia, M.; P.O. Box 33427, Saint Paul, MN 55133-3427 (US). SNUSTAD, Daniel, C.; P.O. Box 33427, Saint Paul, MN 55133-3427 (US). SPAWN, Terence, D.; P.O. Box 33427, Saint Paul, MN 55133-3427 (US).

(74) Agents: WEISS, Lucy, C. et al.; Minnesota Mining and Manufacturing Company, Office of Intellectual Property Counsel, P.O. Box 33427, Saint Paul, MN 55133-3427 (US). ;

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FL, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Title: LIQUID CRYSTAL COMPOUNDS HAVING A CHIRAL FLUORINATED TERMINAL PORTION

(57) Abstract

Fluorine-containing, chiral liquid crystal compounds comprise (a) a chiral fluorochemical terminal portion comprising (i) at least one chiral center, which can optionally be heteroatom-substituted; (ii) a terminal fluoroalkyl, fluoroether, perfluoroalkyl, or perfluoroether group; and (iii) an alkylene or fluoroalkylene group optionally containing at least one catenary ether oxygen atom; (b) a chiral or achiral terminal portion consisting of a hydrocarbon or hydrocarbon ether group, and, when chiral, comprising at least one chiral center, which can optionally be heteroatom-substituted; and (c) a central core connecting the terminal portions; the alkylene or fluoroalkylene group of the chiral fluorochemical terminal portion having at least 3 in-chain atoms and being located between the chiral center of the chiral fluorochemical terminal portion and the central core. The compounds have smectic mesophases or latent smectic mesophases and are useful, for example, in liquid crystal display devices.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albanis	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	F	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Scacgal
	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AU AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD/	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BR	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Paso	GR	Greece		Republic of Macedonia	TR	Turkey
		HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BG	Bulgaria	IE	Ireland	MN	Mongolia	UA	Ukraine
BJ	Benin	IL	Israel	MR	Mauritania	UG	Uganda
BR	Brazil	IS	iceland	MW	Malawi	US	United States of America
BY	Belarus	IT	Italy	MX	Mexico	UZ	Uzbekistan
CA	Canada		•	NE	Niger	VN	Vict Nam
CF.	Central African Republic	JP	Japan		Netherlands	YU	Yugoslavia
CC	Congo	KE	Kenya	NL	***************************************	zw	Zimbabwe
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	LW	Zilindaowe
a	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	Pr	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DR	Germany	u	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

PCT/US98/14624 WO 99/33814

LIQUID CRYSTAL COMPOUNDS HAVING A CHIRAL FLUORINATED TERMINAL PORTION

Field of the Invention

5

15

20

This invention relates to fluorinated chiral smectic liquid crystal compounds, to a process for the preparation of such compounds (and to intermediates for use therein), and to liquid crystal compound mixtures and electrooptical display devices containing such 10 compounds.

Background of the Invention

Devices employing liquid crystals have found use in a variety of electrooptical applications, in particular those which require compact, energyefficient, voltage-controlled light valves, e.g., watch and calculator displays, as well as the flat-panel displays found in portable computers and compact televisions. Liquid crystal displays have a number of unique characteristics, including low voltage and low power of operation, which make them the most promising of the non-emissive electrooptical display candidates currently available.

One of the most important characteristics of a liquid crystal display device is its response time, 25 i.e., the time required for the device to switch from the on (light) state to the off (dark) state. ferroelectric or anti-ferroelectric device, response time $(\tau=\eta/P_*E)$ is proportional to the rotational viscosity (η) of the liquid crystal compound(s) contained within the device and is inversely proportional to their polarization (Ps) and to the applied electric field (E). Thus, response time can be reduced by using compound(s) having high polarizations

PCT/US98/14624 WO 99/33814

or low viscosities, and such compounds are greatly desired in the art.

In the passive addressing of liquid crystal compounds exhibiting a spontaneous polarization, 5 however, low polarization mixtures can be important for the practical operation of a liquid crystal device. Polarization reversal fields are larger for higher polarization mixtures, and polarization reversal fields cause switching or partial switching back to a material's original director alignment. This results in loss of the bistability that is crucial to the passive-matrix driving of ferroelectric liquid crystal devices.

Another potential disadvantage of using high polarization mixtures is the partial switching of their 15 director alignment in response to non-switching (secondary) signals in a driving waveform. continued response or fluctuation of the director causes a large decrease in the contrast ratio of a 20 ferroelectric liquid crystal device.

In addition to fast response times, compounds should ideally possess broad smectic temperature ranges to enable operation of the device over a broad range of temperatures (or should be capable of combination with 25 other liquid crystal compounds having different smectic temperature ranges without adversely affecting the smectic phase behavior of the base mixture).

Summary of the Invention

10

Briefly, in one aspect, this invention provides 30 fluorine-containing, chiral liquid crystal compounds having smectic mesophases or latent smectic mesophases. (Compounds having latent smectic mesophases are those which by themselves do not exhibit a smectic mesophase, but which, when in admixture with compounds having 35

smectic mesophases or with other compounds having latent smectic mesophases, develop smectic mesophases under appropriate conditions.) The chiral liquid crystal compounds of the invention comprise (a) a 5 chiral fluorochemical terminal portion that comprises (i) at least one chiral center (or chiral moiety), which can optionally be heteroatom-substituted; (ii) a terminal fluoroalkyl, fluoroether, perfluoroalkyl, or perfluoroether group (preferably, perfluoroalkyl or perfluoroether); and (iii) an alkylene or 10 fluoroalkylene group optionally containing at least one catenary, i.e., in-chain, ether oxygen atom; (b) a chiral or achiral terminal portion consisting of a hydrocarbon or hydrocarbon ether group and, when chiral, comprising at least one chiral center, which 15 can optionally be heteroatom-substituted; and (c) a central core connecting the terminal portions; the alkylene or fluoroalkylene group of the chiral fluorochemical terminal portion having at least 3 in-20 chain atoms and being located between the chiral center of the chiral fluorochemical terminal portion and the central core (an "extended group").

The chiral fluorochemical terminal portion of the compounds of the invention can be represented by the formula -D-R*-D-R_f, where R* is a cyclic or acyclic chiral moiety containing at least one chiral center (asymmetric carbon atom); R_f is fluoroalkyl, perfluoroalkyl, fluoroether, or perfluoroether; and each D is independently and non-directionally selected from the group consisting of a covalent bond,

-C(=0)-O-C_rH_{2r}-, -O-C_rH_{2r}-, -O-(O=)C-C_rH_{2r}-, -C=C-,

35 $-O+C_sH_{2s}O+_cC_r\cdot H_{2r}\cdot -$, $-C_rH_{2r}-$, $+C_sH_{2s}O+_cC_r\cdot H_{2r}\cdot -$, -O-, -S-,

-CH=CH-, -C(=0)-,

-OSO₂-, -SO₂-, -SO₂-C_rH_{2r}-, -C_rH_{2r}-N-SO₂-, -N(C_pH_{2p+1})-, | C_pH_{2p+1}

5 $-C_rH_{2r}-N-C (=0)-, -CH=N-,$ and combinations thereof, where one or more hydrogen atoms can optionally be replaced with fluorine, and where r and r' are independently integers of 0 to about 10 20, s is independently an integer of 1 to about 10 for each (C_sH_{2s}O), t is an integer of 1 to about 6, and p is an integer of 0 to about 4; with the proviso that at least one chiral center of R* is spaced from the central core by at least 3 in-chain atoms. Preferably, 15 R_f is perfluoroalkyl or perfluoroether; more preferably, R_f is perfluoroether, as the perfluoroether-containing compounds of the invention exhibit, e.g., a broad smectic C mesophase, good compatibility with other smectic C compounds, and advantageous layer spacing 20 behavior. When the Rf group of the fluorochemical terminal portion is perfluoroalkyl or perfluoroether, it can contain small amounts of residual carbon-bonded hydrogen atoms but is preferably completely fluorinated.

In general, the compounds of this invention have a central core comprised of at least one or two rings independently selected from the group consisting of aromatic, heteroaromatic, alicyclic, substituted aromatic, substituted heteroaromatic, and substituted alicyclic rings, the rings being connected one with another by a covalent bond or by chemical groups selected from the group consisting of -COO-, -COS-, -HC=N-, -CH=CH-, -C=C-, and -COSe-. The rings can be fused or non-fused. The heteroatoms within the heteroaromatic rings comprise at least one atom selected from the group consisting of nitrogen, oxygen,

and sulfur. Non-adjacent ring carbon atoms in the alicyclic rings can be substituted by nitrogen, oxygen, or sulfur atoms. When the ring(s) are aromatic, heteroaromatic, substituted aromatic, or substituted heteroaromatic, the non-fused rings of the core are preferably no more than about two in number.

The chiral liquid crystal compounds of the invention exhibit exceptionally wide mesomorphic temperature ranges. When used in electrooptical devices, the compounds provide fast response times upon application of an electric field over broad temperature ranges. This makes them extremely useful in the preparation of mixtures that operate in their active mesomorphic phase in the range of from about -30°C to about 70°C.

10

15

20

25

30

Surprisingly, in comparison with similar compounds having fewer than 3 in-chain atoms between at least one chiral center of the fluorochemical terminal portion and the central core, the compounds of the invention provide comparable electrooptic response speeds in spite of their lower measured polarization values. These lower polarization values in combination with broad mesogenic temperature ranges enable the utilization of liquid crystal mixtures that contain up to 100% of the chiral (optically active) compounds of the invention. In general, mixtures containing a high concentration of the compounds of this invention exhibit more temperature independent switching properties, which is important for the reliable and consistent operation of liquid crystal devices.

Furthermore, the use of high concentrations of liquid crystal compounds having low polarizations also provides a decrease (relative to the use of low concentrations of compounds having high polarizations) in the partial switching response of the resulting

compositions to non-switching (secondary) signals in the driving waveform that is commonly used in the passive addressing of liquid crystal devices. Such a decrease in this response is critical for improving the contrast of a device.

The compounds of the invention are useful in admixture with themselves or with other chiral or achiral liquid crystal compounds (as dopants or as the major components), for electrooptical display applications. The compounds have a number of desirable properties when used in admixture with themselves or with other liquid crystal compounds, preferably compounds having fluorinated terminal portions such as those compounds disclosed, for example, in U.S. Pat. Nos. 4,886,619 (Janulis), 5,082,587 (Janulis), 5,262,082 (Janulis et al.), and 5,658,491 (Kistner et al.).

10

15

For example, the compounds of the invention when admixed with such preferred liquid crystal compounds 20 show excellent compatibility, show a beneficial effect or only a minimal negative effect on the smectic C temperature range of the resulting mixtures (even when present at high concentrations), and provide ferroelectric mixtures having fast electrical response 25 times. Mixtures containing the compounds exhibit favorable alignment, switching, response to an electric field, temperature dependence of response speed, temperature dependence of polarization, contrast, layer structure, and mesomorphic temperature ranges. 30 Compounds of the invention can also be used to optimize mixture properties such as tilt angle, memory angle, spontaneous polarization and its temperature dependence, mesomorphic transition temperatures, switching behavior, birefringence, and the temperature 35 dependence of layer spacing.

In other aspects, this invention also provides liquid crystal compounds (described below) having two fluorochemical terminal portions, a mixture of liquid crystal compounds comprising at least one liquid crystal compound of the invention, a liquid crystal display device containing at least one liquid crystal compound of the invention, and liquid crystal intermediate compounds.

10 Brief Description of the Drawing

These and other features, aspects, and advantages of the present invention will become better understood with regard to the following description, appended claims, and accompanying drawing, wherein:

15 Figure 1 shows a plot of smectic C layer spacing (in Angstroms) versus temperature (in degrees Centigrade) for selected compounds of the invention that were prepared by the procedures given in the designated Examples.

20 Detailed Description of the Invention

A class of the above-described liquid crystal compounds of the present invention can be represented by the general formula I:

where M, N, and P are each independently selected from 30 the group consisting of

5

a, b, and c are each independently zero or an integer
of from 1 to 3, with the proviso that the sum of a + b
+ c be at least 1 (and preferably no greater than 2);

10

each A and B are non-directionally and independently selected from the group consisting of a covalent bond,

15

-C(=0)-Te-, $-(CH_2CH_2)_k-$ where k is 1 to 4, -CH=CH-, -C=C-, -CH=N-, $-CH_2-O-$, -C(=O)-, and -O-;

each X, Y, and Z are independently selected from the group consisting of -H, -Cl, -F, -Br, -I, -OH, -OCH₃, -CH₃, -CF₃, -OCF₃, -CN, and -NO₂;

each 1, m, and n are independently zero or an integer
of 1 to 4;

25

each D is non-directionally and independently selected from the group consisting of a covalent bond, $-C \ (=O) - O - C_r H_{2r} - , \quad -O - C_r H_{2r} - , \quad -O - (O=) C - C_r H_{2r} - , \quad -C = C - , \\ -CH = CH - , \quad -C \ (=O) - ,$

30

$$-O(C_{s}H_{2s}O)_{t}C_{r}\cdot H_{2r}\cdot -, -C_{r}H_{2r}-, +C_{s}H_{2s}O)_{t}C_{r}\cdot H_{2r}\cdot -, -O-, -S-,$$

$$-OSO_{2}-, -SO_{2}-, -SO_{2}-C_{r}H_{2r}-, -C_{r}H_{2r}-N-SO_{2}-, -N(C_{p}H_{2p+1})-,$$

$$C_{p}H_{2p+1}$$

where one or more hydrogen atoms can optionally be replaced with fluorine, and where r and r' are independently integers of 0 to about 20, s is independently an integer of 1 to about 10 for each (C₃H₂₃O), t is an integer of 1 to about 6, and p is an integer of 0 to about 4;

R is selected from the group consisting of $-O - ((C_{q} \cdot H_{2q'-v'} - (R')_{v'}) - O)_{w} - C_{q} H_{2q+1-v} - (R')_{v'},$ $- ((C_{q} \cdot H_{2q'-v'} - (R')_{v'}) - O)_{w} - C_{q} H_{2q+1-v} - (R')_{v'},$ $-C (=O) - O - C_{q} H_{2q+1-v} - (R')_{v'},$ $-O - (O=) C - C_{q} H_{2q+1-v} - (R')_{v'},$

5

20

30

where each R* is independently selected from the group consisting of -Cl, -F, -CF₃, -NO₂, -CN, -H, -C_qH_{2q+1},

-O-(O=)C-C_qH_{2q+1}, -C(=O)-O-C_qH_{2q+1}, -Br, -OH, and -OC_qH_{2q+1} (preferably, -H or -F); q' is independently an integer of 1 to about 20 for each (C_q·H_{2q}·-O); q is an integer of 1 to about 20; w is an integer of 0 to about 10; v is

an integer of 0 to about 2; each v' is independently an integer of 0 to about 2; g is an integer of 1 to about 3; each D is independently and non-directionally selected from the group set forth for D above, with the proviso that the ring containing D has from about 3 to about 10 ring atoms; each W is independently selected from the group consisting of N, CR', and SiR'; and R can be chiral or achiral; and

10 R* is a cyclic or acyclic chiral moiety containing at least one chiral center; and

 $R_{\rm f}$ is fluoroalkyl, perfluoroalkyl, fluoroether, or perfluoroether;

15

with the proviso that there are at least 3 in-chain atoms between the central core structure $-(M)_a-A+(N)_bB+(P)_c-$ and at least one chiral center of R*.

Preferably, R_f is perfluoroalkyl or perfluoroether and R^* is selected from the group consisting of $-O-((C_q\cdot H_{2q'-v'}-(R^!)_{v'})-O)_w-C_qH_{2q-v}-(R^!)_{v'}-,\\ -((C_q\cdot H_{2q'-v'}-(R^!)_{v'})-O)_w-C_qH_{2q-v}-(R^!)_{v'}-,$

$$-C (=0) - O - C_q H_{2q-v} - (R^*)_v - , -O - (O=) C - C_q H_{2q-v} - (R^*)_v - ,$$

D
/ \
---W W---, and -CR'H-(D)g-CR'H-,

30 \/

where each R' is independently selected from the group consisting of -Cl, -F, -CF₃, -NO₂, -CN, -H, -C_qH_{2q+1},

-O-(O=)C-C_qH_{2q+1}, -C(=0)-O-C_qH_{2q+1}, -Br, -OH, and -OC_qH_{2q+1} (preferably, -H, -F, -CF₃, -Br, -OH, or -OCH₃; more preferably, -H, -F, or -CF₃); q' is independently an integer of 1 to about 20 for each ((C_q·H_{2q'-v'}-(R')_{V'})-O); q is an integer of 1 to about 20; w is an integer of 0 to about 10; v is an integer of 0 to about 3; each v' is independently an integer of 0 to about 3; g is an integer of 1 to about 3; each D is independently and non-directionally selected from the group set forth for D above, with the proviso that the ring containing D has from about 3 to about 10 ring atoms; and each W is independently selected from the group consisting of N, CR', and SiR'. More preferably, R_f is perfluoroether.

15 In defining Rf, particularly preferred perfluoroalkyl groups are those which can be represented by the formula $-C_qF_{2q}X'$, where q is as defined above (and, preferably, is at least about 5) and X' is hydrogen or fluorine. Particularly preferred 20 perfluoroether groups are those which can be represented by the formula $-(C_xF_{2x}O)_zC_yF_{2y+1}$, where x is independently an integer of 1 to about 10 for each $(C_xF_{2x}O)$, y is an integer of 1 to about 10, and z is an integer of 1 to about 10. Preferably, the perfluoroether group is linear, x is independently an 25 integer of 1 to about 6 for each $(C_xF_{2x}O)$, y is an integer of 1 to about 6, and z is an integer of 1 to about 6.

Preferred subclasses of the above-described chiral compounds of the invention can be represented by the following formula:

$$R'' - (0)_{j} - G - D' - R^* - (C_{s'} H_{2s'} \cdot 0)_{t'} C_{r''} H_{2r''} - R_{f}$$
 (II)

where R'' is (R'),-CqH2q+1-v, where q is an integer of 2 to about 10, each R' is independently selected from the group consisting of hydrogen, fluorine, chlorine, methyl, and perfluoromethyl, and v is an integer of 1 to about 2;

j is an integer of 0 or 1;

10

G is selected from the group consisting of

where one or more of the aromatic hydrogen atoms can be replaced with fluorine;

D' is selected from the group consisting of $-O+C_sH_{2s}O+_tC_r\cdot H_{2r}$, $-C_rH_{2r}$, $+C_sH_{2s}O+_tC_r\cdot H_{2r}$, and $-O-C_rH_{2r}$, where r and r' are independently integers of 0 to about 12, s is independently an integer of 1 to about 10 for each $(C_sH_{2s}O)$, and t is an integer of 1 to about 3;

R* is selected from the group consisting of

$$-C_qH_{2q-v}-(R^*)_v-$$
 and

where R' is -F, q is an integer of 1 to about 4, v is an integer of 1 to about 3, W is N or CH, and D" is -C(=0)-O- or -CH₂-;

s' in Formula II is an integer of 1 to about 6;

15 t' in Formula II is an integer of 0 or 1;

r" in Formula II is an integer of 1 to about 3; and

 R_f is selected from the group consisting of $-C_qF_{2q+1} \text{ and } -(C_xF_{2x}O)_zC_yF_{2y+1}, \text{ where q is an integer of 1}$ to about 6, x is independently an integer of 1 to about 10 for each $(C_xF_{2x}O)$, y is an integer of 1 to about 8, and z is an integer of 1 to about 5;

25 with the proviso that there are at least 3 in-chain atoms between the central core structure G and at least one chiral center of R*.

More preferably, s', t', and r" in Formula II are each 30 an integer of 1.

The fluorine-containing liquid crystal compounds of the invention can be prepared by a process comprising the steps of (a) mixing at least one compound represented by the formula

PCT/US98/14624 WO 99/33814

$$R_{M}_{A}A_{D}^{-}D^{-}(R^{*})_{X}^{-}B^{*}$$
 (III)
 $X_{1} Y_{m}$

5

with at least one compound represented by the formula

$$B''' + P_c - D - R^* - D - R_f$$

$$|$$

$$|$$

$$Z_n$$
(IV)

or mixing at least one compound represented by the formula

15
$$R_{M} = D - (R^*)_{X} - A^* \qquad (V)$$

$$\downarrow \qquad \qquad \downarrow \qquad \qquad \downarrow$$

with at least one compound represented by the formula

20

$$A''' + (N)_{D}B + (P)_{c} - D - R + - D - R_{f}$$

$$| | | | |$$

$$Y_{m} Z_{n}$$
(VI)

25 or mixing at least one compound represented by the formula

$$R_{M}^{-}A_{D}^{-}D^{-}(R^{+})_{X}^{-}B^{*}$$
 (III)
$$\begin{vmatrix} & & & & & & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & \\ & & & & & \\ & & & \\ & & & \\ & & & & \\ & & & \\ & & & & \\ & & \\ & & & \\ & & & \\ & & \\ & & & \\$$

with at least one compound represented by the formula

$$B^{\dagger\dagger}-D-R_f \qquad (VII),$$

35

where M, N, P, a, b, c, A, B, X, Y, Z, 1, m, n, D, R, R^* , and R_f are as defined above for formula I; x is an integer of 0 or 1; and each A', A'', B', and B'' are

independently selected from the group consisting of -H, -Cl, -Br, -I, -OH, -COOH, -CH(CH₂OH)₂, -SH, -SeH, -TeH, -NH₂, -COCl, -CHO, -OSO₂R_f''', -OSO₂CH₃, -C=CH, dialkyl borane, -CH=CH₂, -NH(C=O)OC_QH_{2Q+1}, -NCO,

5 -OSO₂-cyclo(C₆H₄)-CH₃, -CH₂COOH, and -CH(C(O)O-C_qH_{2q+1})₂, where R_f''' is a perfluoroalkyl group having from 1 to about 10 carbon atoms and q is an integer of 0 to about 20, and with the proviso that (R*)_X-A' can enter into an addition or condensation reaction with A'' and that (R*)_X-B' can enter into an addition or condensation reaction with B'';

and (b) allowing compounds III and IV, compounds V and VI, or compounds III and VII to react, optionally in the presence of suitable coupling agent(s), i.e., reagent(s) which effect coupling. For Formula IV, B'' is preferably selected from the group consisting of -C≡CH, dialkyl borane, and -CH=CH₂ (more preferably -CH=CH₂), and -D-R*-D-R_f is preferably -D'-R*-(C_S, H_{2S}, O)_t, C_T"H_{2T}"-R_f as defined above for Formula II.

In another aspect, liquid crystal compounds of the present invention also include compounds that have two fluorochemical terminal portions and can be represented by the general formula VIII:

30

35

25

where n' is an integer of 0 to about 10 (preferably from about 2 to about 6); j is an integer of 0 or 1; each R_f moiety is independently selected from the group consisting of fluoroalkyl, fluoroether, perfluoroalkyl, and perfluoroether (preferably, perfluoroalkyl or

perfluoroether; more preferably, perfluoroether); and definitions (and preferred definitions) for the other moieties are as stated above for Formula I. Such compounds can be prepared by the above-described methods involving Formulas III, IV, V, VI, and VII, wherein the R moiety is replaced with R_f-CH₂O-C_n·H_{2n}·O-(wherein R_f and n' are as defined for Formula VIII).

Preferred subclasses of the above-described chiral compounds of the invention having two fluorochemical terminal portions can be represented by the following formula:

$$R_f - CH_2O - C_n \cdot H_{2n'}O - G - D' - R^* - (C_s \cdot H_{2s'}O)_t \cdot C_r \cdot H_{2r''} - R_f$$
 (IX)

where n' is an integer of about 2 to about 6 (preferably, 3 or 4); each R_f is independently selected from the group defined above for R_f in regard to Formula II; and all other moieties (and preferred moieties) are as defined above for Formula II.

20 Most of the compounds of the present invention have enhanced smectic mesophases. Mixtures of the compounds of the invention with other liquid crystal materials can be formulated to provide desired transition temperatures and broad mesophase temperature 25 ranges. Such mixtures preferably contain compounds having fluorinated terminal portions, such as those compounds described, for example, in U.S. Pat. Nos. 4,886,619 (Janulis) and 5,082,587 (Janulis) and, most preferably, 5,262,082 (Janulis et al.) and 5,658,491 (Kistner et al.). The liquid crystal compounds of the 30 invention can also be used to prepare ferroelectric liquid crystal devices such as, e.g., those described in U.S. Patent Nos. 5,417,883 (Radcliffe) and 5,641,427 (Shinjo) and in EP 769582 and EP 769543.

PCT/US98/14624 WO 99/33814

The compounds of this invention in admixture with other chiral or achiral liquid crystal compounds may exhibit chiral smectic liquid crystal behavior. Furthermore, many of the perfluoroether groupcontaining liquid crystal compounds of the invention when used alone or when mixed with other liquid crystal compounds of the invention or with achiral, fluorinecontaining liquid crystal compounds (preferably, the perfluoroether group-containing liquid crystal compounds described in U.S. Pat. No. 5,262,082 (Janulis et al.)) exhibit a reduced temperature dependence of the smectic interlayer spacing. This property provides for the spontaneous generation of an essentially bookshelf type layer structure, which is ideal for a ferroelectric liquid crystal device. In general, the 15 compounds of the invention exhibit maintenance or expansion of the smectic C layer spacing with decreasing temperature.

Another advantage of using the materials of this invention in the formulation of liquid crystal mixtures is the low birefringence which can be obtained. low birefringence of the liquid crystal compounds of the invention (relative to their non-fluorinecontaining analogues) allows the fabrication of devices 25 with larger device spacings. Light transmission through, e.g., a surface-stabilized ferroelectric device (as described in U.S. Patent No. 4,367,924) with two polarizers is represented by the following equation:

30

20

$$I = I_o (\sin^2(4\Theta)) (\sin^2(\pi \Delta n d/\lambda))$$

where I_o = transmission through parallel polarizers Θ = material tilt angle

 $\Delta n =$ liquid crystal birefringence

d = device spacing

25

30

 λ = wavelength of light used

5 To maximize the transmission, both sin²(4Θ) and sin²(πΔnd/λ) must be at maximum. This occurs when each term equals one. The first term is a maximum when the tilt angle equals 22.5°. This is a function of the liquid crystal and is constant for a given material at a given temperature. The second term is maximum when Δnd =λ/2. This demonstrates the criticality of the low birefringence of the materials of this invention. Low birefringence allows a larger device thickness, d, for a given wavelength of light. Thus, a larger device spacing is possible while still maximizing transmission, allowing easier device construction.

Objects and advantages of this invention are further illustrated by the following examples, but the particular materials and amounts thereof recited in these examples, as well as other conditions and details, should not be construed to unduly limit this invention.

In the following examples, all temperatures are in degrees Celsius and all parts and percentages are by weight unless indicated otherwise. Commercially available materials were chemically transformed by reaction pathways well-known to those skilled in the art and detailed in the examples. Chemical transformations were comprised of acylation, esterification, etherification, alkylation, and combinations thereof using fluorine-containing and non-fluorine-containing reactants to provide the precursor compounds, which, in turn, were caused to react

together to yield the chiral, fluorine-containing liquid crystal compounds of this invention.

Compounds prepared in the various examples of this invention were characterized by their melting or 5 boiling point, and structures were confirmed by using at least one of the following methods of analysis: chromatography; ¹³C-, ¹H-, and ¹⁹F-NMR; and infrared and mass spectroscopies.

10 EXAMPLES

The 5-alkyl-2-(4-hydroxyphenyl) pyrimidines used in the examples were prepared essentially as described by Zaschke and Stolle in "Synthese niedrigschmelzender Kristallin-Flussiger Heterocyclen; 5-n-Alkyl-2-[4-nalkanovloxy-phenyl]pyrimidine, "Z.Chem. 15, 441-3 15 (1975). (S) - and (R) -2-fluoro-decyl-p-toluenesulfonate were prepared essentially as described by Nohira et al. in Mol. Cryst. Lig. Cryst. 180B, 379 (1990). Fluorinated alcohols were prepared essentially as 20 described in U.S. Patent No. 5,262,082 (Janulis et al.) by sodium borohydride reduction of the corresponding perfluorinated acids (or derivatives), which had been prepared by electrochemical fluorination (ECF) or by direct fluorination (using elemental fluorine) of the corresponding hydrocarbon acids (or derivatives). e.g., the description of ECF given in U.S. Patent No. 2,519,983 (Simons). Direct fluorination is described, e.g., in U.S. Patent No. 5,362,919 (Costello et al.).

30 Example 1

Preparation of (S)-5-Octyl-2-[4-(8-(2-(2-(2-(2-(trifluoromethoxy(tetrafluoroethoxy)tetrafluoroethoxy)-2,2-difluoroethoxy)-7-fluorooctyl)phenyl)pyrimidine

Preparation of Starting Material:

(Trifluoromethoxy(tetrafluoroethoxy) tetrafluoroethoxy) - 2,2-difluoroethoxy) -7-fluorooct-1-ene

5 Into a dry 3 liter flask fitted with a reflux condenser, a nitrogen inlet, a thermocouple, and an addition funnel, were placed magnesium turnings (37.8 g, 1.55 mol) and dry t-butylmethylether (100 mL). 5bromo-1-pentene (225 g, 1.51 mol) was added to the flask dropwise at a rate which maintained the reflux temperature of the reaction mixture (55-6°C). Additional t-butylmethylether (about 1.5 L) was added in 50 mL portions during the addition of the bromide. After the addition was complete, the resulting mixture was heated to reflux for an additional 30 minutes. 15 mixture was then cooled to -65°C. Dilithiotetrachlorocuprate (302 mL, 0.1 M in tetrahydrofuran (THF)) was added, and the resulting reaction mixture was stirred for 45 minutes at -65°C

20 followed by addition of R(-)-epichlorohydrin (125.7 g, 1.36 mol) at a rate not to exceed a reaction mixture temperature of -40°C. The reaction mixture was stirred for an additional 30 minutes, was warmed to -5°C, and was then quenched by

the addition of 250 g of ammonium chloride in 2.5 liters of water. The resulting aqueous phase was extracted with t-butylmethylether (300 mL), and the combined ether layers were washed with ammonium chloride/ammonium hydroxide buffer (2x500 mL) and

saturated sodium chloride (2x500 mL). The solvent was removed under reduced pressure, and the resulting residue was distilled (b.p. = 57 - 72°C at 0.15 torr) to give 183 g of (R)-8-chloro-7-hydroxy-oct-1-ene.

This chlorohydrin was converted in situ to (R)
1,2-epoxy-7-octene and reacted with 2-(2-(2-

(trifluoromethoxy(tetrafluoroethoxy) tetrafluoroethoxy) -2,2-difluoroethanol using the following procedure: (R)-8-chloro-7-hydroxy-oct-1-ene (100 g, 0.61 mol),aqueous potassium hydroxide (45 mL of 45 wt.%), 2-(2-5 (2-(trifluoromethoxy(tetrafluoroethoxy)tetrafluoroethoxy)-2,2-difluoroethanol (291 g, 0.733 mol), Adogen™ 464 (60 g), and 1,2-dimethoxyethane (60 mL) were added to a one liter flask fitted with a mechanical stirrer, an addition funnel, a reflux condenser, and a thermometer. 10 The resulting solution was stirred for one hour at 45°C and then warmed to 60°C, at which time aqueous potassium hydroxide (70 mL of 45 wt%) was added dropwise. This solution was heated for 2 hours at 60°C and then at 70°C for 8 hours. Water (300 mL) was 15 added, and the resulting organic phase was separated and washed with 7 weight % HCl (300 mL). The organic phase was again separated and was concentrated under reduced pressure (25 torr). The resulting crude 20 product was then purified by silica gel chromatography using toluene as eluent to give 268 g of (R)-8-(2-(2-(2-(trifluoromethoxy(tetrafluoroethoxy) tetrafluoroethoxy) -2,2-difluoroethoxy)-7-hydroxyoct-1-ene. 25 Under a nitrogen atmosphere, (R)-8-(2-(2-(2-(trifluoromethoxy(tetrafluoroethoxy) tetrafluoroethoxy) -2,2-difluoroethoxy)-7-hydroxyoct-1-ene (60 g, 0.103 mol) and dry toluene (120 mL) were added to an ovendried flask with stirring. The resulting solution was 30 cooled to -15°C, perfluorobutanesulfonyl fluoride (58.9 g, 0.185 mol) was added, and the resulting reaction mixture was stirred for 5 minutes. 1,8-Diazabicyclo[5.4.0]undec-7-ene (28.7 g, 0.189 mol) was then added at a rate so as not to exceed a temperature

35 of 5°C for the reaction mixture. The reaction mixture

Preparation of Starting Material:

15 4-(5-Octylpyrimidine-2-yl)phenyl Nonafluorobutane Sulfonate

A 12 liter flask fitted with a mechanical stirrer,

a constant addition funnel, a thermometer, and a reflux condenser was charged with of 5-octyl-2-(4hydroxyphenyl)pyrimidine (300 g, 1.05 mol), 20 perfluorobutanesulfonyl fluoride (378 g, 1.25 mol), and tert-butylmethylether (3 L) under positive nitrogen pressure and was cooled with an ice bath to 16°C. 1,8-Diazabicyclo[5.4.0]undec-7-ene (180 g, 1.18 mol) was added to the resulting mixture over 25 minutes, while 25 maintaining the temperature of the mixture below 20°C. After the addition was complete, the mixture was stirred at room temperature for 2 hours, and then 3 liters of water was added. The resulting aqueous phase was separated from the resulting organic phase, and the organic phase was washed with a mixture of 2.25 liters of water and 0.75 liters of concentrated HCl. solvent was removed from the organic phase under reduced pressure to yield 697 g of crude product, which was recrystallized from ethanol to yield 4-(5-octyl

pyrimidine-2-yl)phenyl nonafluorobutane sulfonate (499 g, 84% yield).

Preparation of Product:

5 A 1 liter flask fitted with a magnetic stirring bar, a thermocouple, and a nitrogen inlet was charged with anhydrous tetrahydrofuran (230 mL) and 9borabicyclo[3.3.1]nonane (229 mL, 0.5 M in THF) under a nitrogen atmosphere. The resulting solution was cooled 10 (trifluoromethoxy (tetrafluoroethoxy) tetrafluoroethoxy) -2,2-difluoroethoxy)-7-fluorooct-1-ene (50 g, 95.4 mmol) was added via syringe at a rate such that the temperature of the resulting mixture was maintained below 7°C. The mixture was stirred for 14 hours, and 15 then PdCl₂(Ph₃P)₂ (2.0 g, 2.86 mmol), NaOH (11.4 g, 286.1 mmol), and 4-(5-octyl pyrimidine-2-yl)phenyl nonafluorobutane sulfonate (54.0 g, 95.4 mmol) were added. The resulting mixture was heated to 50°C for 1.5 hours and was then poured into 1 liter of water. The resulting product was extracted with toluene (3x100) mL), and the toluene extracts were washed with water (3x100 mL). The solvent was removed under reduced pressure, and the resulting crude brown product was 25 chromatographed through 200 g of silica gel (10 volume % ethyl acetate in heptanes eluent) and was further purified by recrystallization from heptane at -20°C followed by Kugelrohr distillation (b.p. 195 - 197°C at 0.02 torr; yield 54.7 g).

30

Examples 2 through 140

Example 2 - 140 were prepared essentially as described in Example 1 using homologous starting materials according to the following general Scheme 1

(where n is an integer of 0 to 7 and $R_{\rm f}$ and R are as defined above for Formula I.

Scheme 1

5

Example 141

Preparation of 5-Hexyloxy-2-[4(-6-(2-pentafluoroethoxy)-2,2-difluoroethoxy)-(S)-7-

10 fluorooctyl)phenyl]pyrimidine

The starting material, 5-hexyloxy-2-[4(-6-(2-pentafluoroethoxy)-2,2-difluoroethoxy)-(R)-7-hydroxyoctyl)phenyl]pyrimidine, was prepared by combining 5-hexyloxy-2-[4-(1,2-

epoxyhexyl)phenyl]pyrimidine (3.0 g, 7.85 mmol; which can be prepared from (R)-1,2-epoxy-7-octene and 4-(5-hexyloxypyrimidine-2-yl)phenyl trifluoromethanesulfonate by the method described in

Oh-e, T. et. al., J. Org. Chem. <u>58</u>, 2201 (1993).), 220 pentfluoroethoxy-2,2-difluoroethanol (2.04 g, 9.42 mmol), AdogenTM 464 (0.4 mL), potassium hydroxide (1.0 mL 50 weight % in H₂O), and THF (1 mL). The resulting mixture was heated at 75°C for 12 hours. The resulting

alcohol was purified by recrystallization from acetonitrile (yield 3.99 g).

The title compound was prepared by dropwise addition of 5-hexyloxy-2-[4(-6-(2-pentafluoroethoxy)-2,2-difluoroethoxy)-(R)-7hydroxyoctyl)phenyl]pyrimidine (3.99 g, 6.68 mmol) in THF (13 mL) to a solution of diethylaminosulfur trifluoride (1.2 g, 7.35 mmol) in THF (22 mL) at -50°C. The resulting mixture was then warmed to 0°C and subsequently cooled to -50°C before addition of pyridine (1.1 mL). The mixture was stirred at room temperature for 12 hours and was then added to a slurry of silica gel (15 g in 100 mL diethyl ether). Solvent was removed under reduced pressure, and the resulting 15 product was purified by column chromatography (silica gel), eluting with 10:1 hexane/ethyl acetate, followed by Kugelrohr distillation (b.p. 156-165°C at 0.1 torr; yield 0.93 g).

20 Examples 142 through 163

25

Examples 142 - 163 were prepared essentially as described in Example 141 using homologous materials as shown in the following general Scheme 2. In Scheme 2, n is an integer of 4 to 6, and $R_{\rm f}$ and R are as defined above for Formula I.

Scheme 2

PCT/US98/14624 WO 99/33814

Examples 164 through 175

10

Examples 164 - 175 were prepared essentially as described in Example 141 using (S) 3-(3-butenyloxy)-5 1,2-epoxy-propane (prepared from (R) epichlorohydrin and 3-buten-1-ol using BF3 Et2O and subsequent treatment with base) in place of (R)-1,2-epoxy-7-octene according to the following general Scheme 3. In Scheme 3, n is an integer of 4, and R_f and R are as defined above for Formula I.

Scheme 3

$$R \longrightarrow (CH_2)_{\Pi}OCH_2 \longrightarrow (CH_2)_{\Pi}OCH_2 \longrightarrow (CH_2)_{\Pi}OCH_2 \longrightarrow (CH_2)_{\Pi}OCH_2 \hookrightarrow (CH_2)$$

Examples 176 through 186

Examples 176 - 186 were prepared essentially as 15 described in Example 1 using (R) 1-chloro-3-(5hexenyloxy) - 2-propanol (prepared from (R) epichlorohydrin and 5-hexen-1-ol using BF₃·Et₂O) in place of (R)1-chloro-7-octen-2-ol according to the following general Scheme 4 (where n is an integer of 4 to 6, and R and R_f are as defined above for Formula I): 20 Scheme 4

Example 187

Example 187 was prepared essentially as described in Example 1 using (S) 1-chloro-3-(5-octenyloxy)- 2
5 propanol (prepared from (R) epichlorohydrin and 7octen-1-ol using BF₃ Et₂O) in place of (R) 1-chloro-7octen-2-ol.

Examples 188 through 201

10 Examples 188 - 201 were prepared essentially as described in Example 176 using 5-benzyloxy-2-(4trifluoromethanesulfonyloxyphenyl) pyrimidine in place of 5-octyloxy-2-(4-nonafluorobutanesulfonyloxyphenyl) pyrimidine. The resulting compound was treated with 10 weight % palladium on carbon under hydrogen pressure 15 (3100 torr) to obtain 5-hydroxy-2-[4-(6-(3-(2-(2-(2-(trifluoromethoxy(tetrafluoroethoxy) tetrafluoroethoxy) -2,2-difluoroethoxy)-(S)-2fluoropropyloxy)hexyl)phenyl]pyrimidine. This material was then treated under basic conditions with the 20 corresponding chloride or methane sulfonate to give the final products. The procedure is shown in the following general Scheme 5 (where Bn is a benzyl protecting group, n is an integer of 3 or 4, m is an 25 integer of 0 or 1, and R_f and R are as defined above for Formula I):

Scheme 5

Example 202

5 Preparation of 5-Octyloxy-2-[4-(2-(3-(2-(2-(2-(nonafluorobutoxy) tetrafluoroethoxy) -2,2-difluoroethoxy)-(R)-2-

fluoropropoxy) ethoxy) phenyl]pyridine

The title compound was prepared by combining 5octyloxy-2-[4-hydroxyphenyl]pyrimidine (2.2 g, 7.4 10 mmol), 2-(3-(2-(2-(nonafluorobutoxy) tetrafluoroethoxy) -2,2-difluoroethoxy) - (R) -2-hydroxypropoxy) ethyl chloride (4.2 g, 7.4 mmol), and potassium carbonate (1.2 g, 8.9)mmol) in a 1:1 mixture of acetonitrile and dimethyl formamide. After heating overnight, the resulting 15 mixture was poured into deionized water (40 mL), was filtered, and the resulting product purified by chromatography, eluting with 4:1 and then 2:1 hexane/ethyl acetate (yield 2.56 g). The resulting chiral (R)-hydroxy compound (2.5 g, 3.0 mmol) was treated with diethylaminosulfur trifluoride (0.58 g, 3.6 mmol) to produce the title compound, which was purified by recrystallization from ethanol, followed by

Kugelrohr distillation (b.p. 210-20°C at 0.4 torr; yield 1.42 g).

Example 203

5 Preparation of 5-heptyl-2-[4-(3-(3-(2-(2-(2-(nonafluorobutoxy) tetrafluoroethoxy) -2,2-difluoroethoxy)-(S)-2-

fluoropropoxy) propoxy) phenyl] pyrimidine

The starting material, 3-(3-(2-(210 (nonafluorobutoxy)tetrafluoroethoxy)-2,2difluoroethoxy)-(S)-2-fluoropropoxy)propyl chloride,
was prepared by combining
3-(2-(2-(nonafluorobutoxy)tetrafluoroethoxy)-2,2difluoroethoxy)-(S)-2-fluoropropanol (20 g, 39.4 mmol)
and 1-bromo-3-chloropropane (18.6 g, 118 mmol). The
resulting compound (2.0 g, 3.4 mmol) was then combined
with 5-heptyl-2-(4-hydroxyphenyl)pyrimidine (0.9 g, 3.4
mmol) in acetonitrile/dimethyl formamide (1:1, 20 mL)
using essentially the procedure of Example 8 of
International Patent Publication No. WO 96/33251. The

resulting crude product was further purified by chromatography, eluting with 30:1 toluene/ethyl acetate, followed by Kugelrohr distillation (180-90°C at 0.01 torr; yield 0.96 g).

25

Example 204

Preparation of 5-Hexyloxy-2-[4-(3-(3-(2-(2-(nonafluorobutoxy) tetrafluoroethoxy) -2,2-difluoroethoxy)-(S)-2-

30 fluoropropoxy)propoxy)phenyl]pyrimidine

The title compound was prepared essentially as described in Example 8 of International Patent Publication No. WO 96/33251 by combining 3-(3-(2-(2-(nonafluorobutoxy)tetrafluoroethoxy)-2,2-

35 difluoroethoxy)-(S)-2-fluoropropoxy)propyl chloride

(3.0 g, 5.1 mmol) with 5-hexyloxy-2-(4-hydroxyphenyl)pyrimidine (1.4 g, 5.1 mmol). The resulting crude product was purified by Kugelrohr distillation (b.p. 170-80°C at 0.01 torr).

5

35

Example 205

Preparation of 5-Octyloxy-2-[4-(4-(2-(2-(2-(nonafluorobutoxy) tetrafluoroethoxy) -2,2-difluoroethoxy)-(S)-3-fluorobutoxy) phenyl]pyrimidine

The starting material, 4-(2-(2-(nonafluorobutoxy)tetrafluoroethoxy)-2,2-difluoroethoxy)-(S)-3-fluorobutane-1-methanesulfonate, was prepared by the following procedure: 4-benzyloxy-(R)-1,2-epoxybutane (8.0 g, 44.9 mmol, prepared

essentially as described by J. A. Frick in Synthesis 7, 621 (1992)) was combined with 2-(2- (nonafluorobutoxy) tetrafluoroethoxy)-2,2-difluoroethoxy (23.3 g, 53.9 mmol), potassium hydroxide (3.0 g, 53.9 mmol, aqueous) in tetrahydrofuran (3 mL) and refluxed

for 3 hours to produce 4-(2-(2-(2-(nonafluorobutoxy)tetrafluoroethoxy)-2,2-difluoroethoxy)-(R)-3-hydroxybutane-1-methanesulfonate. This (R)-hydroxy compound (20 g, 32.8 mmol) was treated with diethylaminosulfur

25 tetrafluoride (6.3 g, 39.3 mmol) and was then hydrogenated using Pd(OH)₂ on carbon to remove the benzyl protecting group.

The title compound was prepared by combining 5-octyloxy-2-(4-hydroxyphenyl)pyrimidine (1.1 g, 3.8 mmol) and 4-(2-(2-

(nonafluorobutoxy) tetrafluoroethoxy) -2,2-difluoroethoxy) - (S) -3-fluorobutane-1-methanesulfonate (2.3 g, 3.8 mmol) using essentially the procedure of Example 8 of International Patent Publication No. WO 96/33251. The resulting crude product was further

purified by chromatography, followed by Kugelrohr distillation (yield 1.92 g).

Example 206

5 Preparation of 5-Hexyloxy-2-[3-(4-(2-(2-(2-(nonafluorobutoxy) tetrafluoroethoxy)-2,2-difluoroethoxy)-(S)-3-

fluorobutoxy) propyl) phenyl] pyrimidine

The title compound was prepared by adding 10 (nonafluorobutoxy) tetrafluoroethoxy) -2, 2difluoroethoxy) - (S) -3-fluorobutoxy) prop-1-ene (3.5 g, 6.2 mmol, prepared by addition of 3-bromopropene to 4-(2-(2-(nonafluorobutoxy) tetrafluoroethoxy)-2,2difluoroethoxy)-(S)-3-fluorobutanol) to a mixture of 5hexyloxy-2-[trifluoromethylsulfonyloxyphenyl]pyrimidine 15 (2.5 g, 6.22 mmol), 9-borabicyclononane (12.4 mL of 0.5 M in THF), PdCl₂dPPF ([1,1'-bis(diphenylphosphino)ferrocene)palladium(II) chloride, 50 mg, 0.062 mmol), and K_3PO_4 (2.8 g, 13.1 mmol) in dioxane (17 mL) at a temperature less than 5°C. After stirring the resulting 20 mixture at 100°C for 16 hours, water was added, and the mixture was extracted with toluene. The combined toluene extracts were dried, and the resulting crude product was purified by chromatography, eluting first 25 with 10:1 then 4:1 hexanes/ethyl acetate, followed by Kugelrohr distillation (b.p. 180°C at 0.01 torr; yield $0.95 \, a)$.

Example 207

35

(nonafluorobutoxy) tetrafluoroethoxy) -2, 2-

difluoroethoxy)-(S)-3-fluorobutanol (2.0 g, 3.8 mmol), 5-octyloxy-2-[bromomethylphenyl]pyrimidine (prepared essentially as described in EP 474196, 1.44 g, 3.8 mmol), potassium hydroxide (0.21 g, 3.8 mmol), and

AdogenTM 464 (0.15 g) in tetrahydrofuran and then heating the resulting mixture overnight at 75°C. The resulting crude product was purified by chromatography, eluting with 8:1 hexanes/ethyl acetate, followed by Kugelrohr distillation (yield 0.45 g).

10

Example 208

Preparation of 5-Hexyloxy-2-[4-(4-(2-(2-(nonafluorobutoxy) tetrafluoroethoxy) -2,2-difluoroethoxy) -(S) -3-

15 fluorobutoxy) butoxy) phenyl]pyrimidine

The starting material, 4-(4-(2-(2-(nonafluorobutoxy) tetrafluoroethoxy) -2, 2difluoroethoxy) - (S) -3-fluorobutoxy) butyl bromide, was prepared by combining 1,4-dibromobutane (4.9 g, 22.8 20 mmol) with 2-(2-(nonafluorobutoxy) tetrafluoroethoxy) -2,2-difluoroethoxy)-(S)-3-fluorobutanol (4.0 g, 7.6 mmol). The title compound was prepared essentially as described in Example 8 of International Patent (nonafluorobutoxy) tetrafluoroethoxy) -2, 2-25 difluoroethoxy) - (S) -3-fluorobutoxy) butyl bromide (2.7) q, 4.1 mmol) with 5-hexyloxy-2-(4hydroxyphenyl)pyrimidine (1.1 g, 4.1 mmol). resulting crude product was purified by chromatography, eluting with 6:1 hexanes/ethyl acetate (yield 0.58 g). 30

Example 209

Preparation of 5-Octyl-2-[4-(4-(2-(2-(nonafluorobutoxy) tetrafluoroethoxy) -2,2-

difluoroethoxy) - (S) -3-

fluorobutoxy) butoxy) phenyl]pyrimidine

The title compound was prepared essentially as described in Example 8 of International Patent

5 Publication No. WO 96/33251 by combining 4-(4-(2-(2-(nonafluorobutoxy)tetrafluoroethoxy)-2,2-difluoroethoxy)-(S)-3-fluorobutoxy)butyl bromide (2.6 g, 3.95 mmol) with 5-octyl-2-(4-hydroxyphenyl)pyrimidine (1.1 g, 3.95 mmol). The resulting crude product was purified by chromatography, eluting with 6:1 hexanes/ethyl acetate (yield 2.4 g).

Example 210

derivative

Preparation of 5-Heptyl-2-[4-(7-(2-(2-

15 (nonafluorobutoxy) tetrafluoroethoxy) -2,2difluoroethoxy) - (R) -6-fluoroheptyloxy) phenyl] pyrimidine

The starting material, 7-(2-(2(nonafluorobutoxy)tetrafluoroethoxy)-2,2difluoroethoxy)-(R)-6-fluoroheptane-1-methanesulfonate,

was prepared by the following procedure: 7-(2-(2(nonafluorobutoxy)tetrafluoroethoxy)-2,2difluoroethoxy)-(R)-6-fluorohept-1-ene (10 g, 18.8
mmol) was treated with BH₃·THF (9.4 mmol) in
tetrahydrofuran, followed by oxidation with hydrogen

peroxide (30% aqueous, 9.4 mmol) to produce the
corresponding heptanol. This heptanol (8.9 g, 15.7
mmol) was treated with methanesulfonyl chloride (1.98
g, 17.3 mmol) to produce the methanesulfonate

The title compound was prepared by combining 5heptyl-2-(4-hydroxyphenyl)pyrimidine (1.1 g, 3.8 mmol)
and 4-(2-(2-(nonafluorobutoxy)tetrafluoroethoxy)-2,2difluoroethoxy)-(S)-3-fluoropropoxy)butane-1methanesulfonate (2.3 g, 3.8 mmol) essentially as
described in Example 8 of International Patent

Publication No. WO 96/33251. The resulting crude product was further purified by recrystallization from heptane, then from ethanol, followed by Kugelrohr distillation (b.p. 200°C at 0.1 torr; yield 1.79 g).

5

Example 211 Preparation of 5-Hexyloxy-2-[4-(7-(2-(2-(nonafluorobutoxy) tetrafluoroethoxy) -2,2difluoroethoxy) - (R) -6-fluoroheptyloxy) phenyl]pyrimidine The title compound was prepared by combining 5-10 hexyloxy-2-(4-hydroxyphenyl)pyrimidine (0.36 g, 1.32 mmol) and 4-(2-(2-(nonafluorobutoxy) tetrafluoroethoxy) -2,2difluoroethoxy) - (S) -3-fluoropropoxy) butane-1-15 methanesulfonate (0.85 g, 1.32 mmol) essentially as described in Example 8 of International Patent Publication No. WO 96/33251. The resulting crude product was further purified by chromatography, eluting with 10:1 hexanes/ethyl acetate, followed by Kugelrohr 20 distillation (b.p. 190-210°C at 0.01 torr; yield 0.67

Example 212

g).

Preparation of 5-Octyloxy-2-[4-(7-(2-(2-25 (nonafluorobutoxy) tetrafluoroethoxy)-2,2difluoroethoxy)-(R)-6-fluoroheptyloxy)-2,3difluorophenyl]pyrimidine

The title compound was prepared essentially as described in Example 211 by combining 5-octyloxy-2-(4-30 hydroxyphenyl)-2,3-difluoropyrimidine and 4-(2-(2-(nonafluorobutoxy)tetrafluoroethoxy)-2,2-difluoroethoxy)-(S)-3-fluoropropoxy)butane-1-methanesulfonate essentially as described in Example 8 of International Patent Publication No. WO 96/33251.

The resulting crude product was further purified by

chromatography, eluting with 10:1 hexanes/ethyl acetate, followed by Kugelrohr distillation.

Example 213

5 Preparation of 5-Octyloxy-2-[4-(7-(2-(2-(2-(nonafluorobutoxy) tetrafluoroethoxy) -2,2-difluoroethoxy) - (R) -6-fluoroheptyloxy) -2,3-difluorophenyl]pyrimidine

The title compound was prepared essentially as

10 described in Example 211 by combining 5-octyloxy-2-(4-hydroxyphenyl)-3-fluoropyrimidine and 4-(2-(2-(nonafluorobutoxy)) tetrafluoroethoxy)-2,2-difluoroethoxy)-(S)-3-fluoropropoxy) butane-1-methanesulfonate essentially as described in Example 8

15 of International Patent Publication No. WO 96/33251.

The resulting crude product was further purified by chromatography, eluting with 10:1 hexanes/ethyl acetate, followed by Kugelrohr distillation.

20 Example 214

Preparation of 5-(2-(S)-Fluorodecyloxy-2-[4-(6-(2-(2-(nonafluorobutoxy) tetrafluoroethoxy)-2,2-difluoroethoxy)-(S)-5-fluorohexyl)phenyl]pyrimidine

The title compound was prepared by adding

(nonafluorobutoxy) tetrafluoroethoxy)-2,2
difluoroethoxy)-(S)-5-fluorohex-1-ene (4.0 g, 7.5 mmol)

to a mixture of 5-(2-(S)-fluorodecyloxy-2-[6-(2-(2
(nonafluorobutoxy) tetrafluoroethoxy)-2,2
difluoroethoxy)-(S)-5-fluorohexyl) phenyl] pyrimidine

(3.6 g, 7.5 mmol), 2-(2, 9-borabicyclononane (15 mL of

0.5 M in THF), PdCl₂dPPF (60 mg, 0.075 mmol), and K₃PO₄

(3.3 g, 15.8 mmol) in dioxane (17 mL) at a temperature

less than 5°C. After stirring the resulting mixture at

room temperature overnight, water was added, and the

35 mixture was extracted with toluene. The combined

toluene extracts were dried, and the resulting crude product was purified by chromatography, eluting with 10:1 hexanes/ethyl acetate, followed by Kugelrohr distillation (b.p. 190-210°C at 0.01 torr) and recrystallization from heptane (yield 2.2 g).

Example 215

Preparation of 5-Hexyloxy-2-[4-(3-(2-(2-(nonafluorobutoxy) tetrafluoroethoxy) -2,2-

10 difluoroethoxy)) - (R) -2-fluoropropyloxy) - (R) -2methylpropyloxy) phenyl]pyrimidine

The starting material, 3-(2-(2-(nonafluorobutoxy)tetrafluoroethoxy)-2,2-difluoroethoxy))-(R)-2-fluoropropyloxy)-(R)-2-

- 15 methylpropane-1-methanesulfonate, was prepared as follows: (S)-2-methyl-3-bromopropanol was alkylated with benzyl bromide to produce (S)-2-methyl-3-bromo-1-benzyloxypropane, which was then combined with 3-(2-(2-(nonafluorobutoxy)tetrafluoroethoxy)-2,2-
- difluoroethoxy))-(R)-2-fluoropropanol, followed by
 hydrogenation with 10% Pd/C to remove the benzyl
 protecting group. The title compound was prepared by
 combining 5-hexyloxy-2-(4-hydroxyphenyl)pyrimidine (0.7
 g, 2.58 mmol) and 3-(2-(2-
- 25 (nonafluorobutoxy) tetrafluoroethoxy) -2,2difluoroethoxy)) (R) -2-fluoropropyloxy) (R) -2methylpropane-1-methanesulfonate (1.7 g, 2.58 mmol)
 essentially as described in Example 8 of International
 Patent Publication No. WO 96/33251. The resulting
 30 crude product was further purified by chromatography,
 eluting with 10:1 hexanes/ethyl acetate, and was
 recrystallized from heptane, followed by Kugelrohr

g).

distillation (b.p. 180-190°C at 0.02 torr; yield 1.28

Example 216

Preparation of 5-Heptyloxy-2-[4-(3-(2-(2-(nonafluorobutoxy) tetrafluoroethoxy) -2,2-difluoroethoxy))-(S)-1-

5 (trifluoromethyl)ethyl)propyl)phenyl]pyrimidine

The title compound was prepared by adding 3-(2-(2-(nonafluorobutoxy)tetrafluoroethoxy)-2,2-difluoroethoxy))-(S)-1-(trifluoromethyl)ethyl)prop-1-ene (6.0 g, 10.3 mmol, prepared by addition of 3-

10 bromopropene to 2-(2-(2-

(nonafluorobutoxy)tetrafluoroethoxy)-2,2difluoroethoxy)-(S)-1-(trifluoromethyl)ethanol) to a
mixture of 5-heptyloxy-2-

[trifluoromethylsulfonyloxyphenyl]pyrimidine (4.3 g,

- 15 10.3 mmol), 9-borabicyclononane (20.6 mL of 0.5 M in THF), PdCl₂dPPF (82 mg, 0.1 mmol), and K₃PO₄ (2.8 g, 13.1 mmol) in dioxane (17 mL) at a temperature less than 5°C. After stirring the resulting mixture at 100°C for 16 hours, water was added, and the mixture was
- extracted with toluene. The combined toluene extracts were dried, and the resulting crude product was purified by chromatography, eluting with 10:1 hexanes/ethyl acetate, and was recrystallized from heptane, followed by Kugelrohr distillation (b.p. 160-
- 25 70°C at 0.02 torr; yield 3.04 g).

Example 217

Preparation of 5-Hexyloxy-2-[4-(2-(2-(2-(2-(trifluoromethoxy) tetrafluoroethoxy)

30 tetrafluoroethoxy) -2,2-difluoroethoxy) - (R) -8fluorononyloxy) phenyl pyrimidine

The starting material, 2-(2-(2-(2-(trifluoromethoxy)tetrafluoroethoxy)-(2,2-difluoroethoxy)-(R)-8-fluorononyl-1-

35 methanesulfonate, was prepared by hydroboration of 2-

(2 - (2 -

(trifluoromethoxy) tetrafluoroethoxy) tetrafluoroethoxy) - 2,2-difluoroethoxy) - (R) -8-fluoronon-1-ene using BH₃ in tetrahydrofuran, followed by mesylation of the

5 resulting nonanol. The title compound was prepared by combining 5-hexyloxy-2-(4-hydroxyphenyl)pyrimidine (2.0 g, 7.8 mmol) and 2-(2-(2-

(trifluoromethoxy) tetrafluoroethoxy)

tetrafluoroethoxy) -2, 2-difluoroethoxy) -(R) -8-

fluorononyl-1-methanesulfonate (4.9 g, 7.8 mmol) essentially as described in Example 8 of International Patent Publication No. WO 96/33251. The resulting crude product was further purified by recrystallization from hexanes, followed by chromatography (eluting with

15 10:1 hexanes/ethyl acetate) and then by Kugelrohr distillation (b.p. 185-95°C at 0.01 torr; yield 2.3 g).

Example 218

Preparation of 5-Heptyloxy-2-(4-[5-(3-(2-(2-

20 (nonafluorobutoxy) tetrafluoroethoxy) -2,2difluoroethoxy)) - (S) -2-(fluoropropoxy) -2,2,3,3,4,4hexafluoropentyloxy) phenyl] pyrimidine

The title compound was prepared essentially as in Example 97 of International Patent Publication No.

25 96/15092 by combining 5-heptyloxy-2-(4hydroxyphenyl)pyrimidine with 5-(3-(2-(2(nonafluorobutoxy)tetrafluoroethoxy)-2,2difluoroethoxy))-(S)-2-(fluoropropoxy)-2,2,3,3,4,4hexafluoropentyl-1-butanesulfonate. The resulting
30 product was purified by chromatography, followed by
Kugelrohr distillation (b.p. 200-5°C at 0.008 torr).

Example 219

Preparation of 5-Heptyloxy-2-(4-[4-(3-(2-(2-

35 (nonafluorobutoxy) tetrafluoroethoxy) -2,2-

difluoroethoxy))-(S)-2-(fluoropropoxy)-2,2,3,3,tetrafluorobutyloxy)phenyl]pyrimidine

The title compound was prepared essentially as in Example 97 of International Patent Publication No.

5 96/15092 by combining 5-heptyloxy-2-(4-hydroxyphenyl)pyrimidine with 4-(3-(2-(2-(nonafluorobutoxy)tetrafluoroethoxy)-2,2-difluoroethoxy))-(S)-2-(fluoropropoxy)-2,2,3,3-tetrafluorobutyl-1-butanesulfonate. The resulting product was purified by chromatography, followed by Kugelrohr distillation (b.p. 195-200°C at 0.01 torr).

The compounds of the Examples were evaluated for transition temperatures by differential scanning calorimetry (DSC) and/or optical observation of material phase changes using a hot stage and a polarizing microscope. The transition temperatures (°C) were obtained upon cooling through the isotropic state (I) to the smectic A mesophase (S_A), the smectic C mesophase (S_C), and higher order mesophases (M1 and M2) and are set forth in Table 1 below.

Table 1.

20

Ex. No.	Structure	I to SA	to S _C	to S _{M1}	to K	to S _C	to S _A
1	California Control significant of the control of th	79.3	56.7	-4.2		22.2	59.2
2	C ₂ M ₂ C-C ₃ N ₂ C ₃ C ₃ F ₃ CC ₃ CC	90.9	61.3	41.5		46.6	63.2
3	C4H30-CH312F40C4F4	92.3	70.1	43.2		48.2	72.5
4	C4H40-CH2h2-CH2C4F40C4F4	92.1	57.6	41.1		52.8	59.5
5	C1H110-CH12K-20C1F40CF3	83.4		34.3			48.7
6	C ₁ H ₁₁ O—OH ₂ h OCH ₂ CF ₃ hOCF ₃	95	61	27.7		37.7	63.3

Ex. No.	Structure	I to SA	to S _C	to S _{M1}	to K	to Sc	to S _A
7	C+H+10-CH+CF+0C+F+0C+F+	89.6		32.4			45.2
8	COMHO CHIZE FOC F	84.1		30			47.9
9	Call HO CHARLAND CHARLAND CAP	95	50	38			
10	Cylly CH32 CH3CF3CC4F3	91.7	59.7	25.8		34.1	62
11	CgH 440—CH36 CCH3C3F 60C F7	98.4	63.6	34		42.7	65.9
12	C ₄ H ₁₁ O—ON—OCH ₂ CF ₂ OC ₄ F ₆	83.5		29.9			42.9
13	CPH410-OCH1CF10C1F40C4F4	93.1	69.6	27.4		34.7	72.1
14	C+H110-CH26-F-0C+F-	91.5	54.8	23.5		40.8	57.6
15	C,M,1———————————————————————————————————	72.8	40.9	21.4		33.9	43.6
16	C_H,	67.2	31.5	17.2		25	33.9
17	C ₀ H ₁ y-CH ₁ CF,OC,F ₀ CC,F ₀	65.9		26.1			40.5
18	C ₀ H ₁ F ₁ CC ₂ F ₄ CC ₃ CC	67.7	38	18.2		26.6	40.3
19	C ₉ M ₁₂ —CH ₂ M-OCH ₆ CF ₅ OC ₅ F ₆ OC ₅ F ₆	72.8	48.4	19.2		26.1	51
20	CeMero-CM1CF1OC1F4OCF1	92		14.9			31.3
21	C ₄ H ₄ y ₂ O	103.4	74.6	12.1		33.4	76.2
22	C ₄ H _{4,1} O————————————————————————————————————	98.3	53	19.4		41.5	
23	C#H 250—CH 262 F 40C 2F 1	91.8		13.5			27.2
24	C ₂ M ₁₂ O————————————————————————————————————	98.6	74.1	11.6		30.5	76.3

Ex. No.	Structure	It SA	to S _C	to S _{M1}	to K	to S _C	t S _A
25	Call do CHAR CALL DCHACA COCAL	103.1	69.6	15.3		29.9	72
26	CeM 120-CH2C3F 40C4F8	98.1	70.3	2.6		17.6	72.6
27	C ₁ M ₄ _E —C ₁ C ₁ M ₂ M ₂ C ₂ C ₃ C ₃ C ₃ C ₃ C ₄ C ₅	80.4	46.7	8		24.8	49.4
28	C,He, CHOM, CF,OC,F,OC,F,	73	19	13			32
29	C7H16————————————————————————————————————	65.4	9	7			16.3
30	C,H16————————————————————————————————————	78	53	<rt< td=""><td></td><td></td><td></td></rt<>			
31	CHI15—CH236 OCH2C3FeOC4Fe	73.1	35.2	-1.7		21.3	37.4
32	C ₁ H ₁ 0 CH ₂ L CCH ₂ CF ₃ OCF ₃ OCF ₃	92.4	58.1	5.9		20	60.8
33	C ₂ H ₁₃ O—O (CH ₂) CCH ₂ C ₃ F ₄ OC ₅ F ₄ OCF ₃	100.3	74.7	-15.1		12.5	77.1
34	C ₂ H ₁₃ O=CH ₂ L ₃ CH ₂ CF ₁ OC ₃ F ₄ OC ₃ F ₄ OC ₃ F ₆	98.7	75.5	0		28.4	77.8
35	C+H+15O	93.1	59.5	5		21.6	62
36	C,H150-CH2C3F60C3F6	100	73.6	18.1		29.1	76.1
37	CHH 150-CH 26-F-0C-F-1	103.7	80.2	1.1		21	82.4
38	с,н _н о—С сн ₂ ссн ₂ ссн ₂ ссн ₂ ссн ₂ сг ₂ сг ₂ ссн ₂ сг ₂	90.8	67.6	1.1		13.6	70.6
39	C 1410-CH234-OCH2C2F4OC4F	98.6	80.7	-14.9)	15.3	82.8
40	CoH1CF1(OC1Fa)rOCF	78.7	50.4	-4.5		19.6	53.5
41	C,H,F,CCF	74	41	-0.1		22.5	45.1

Er. No.	Structure	I to SA	to S _C	to S _{M1}	to K	to S _C	to S _A
42	C_H17—CH23s CH2C,F40C,F6	72.5	47	-0.1		24.5	
43	C ₀ H ₁ ,rO	88.1	61.9	-15.1		29.5	64.4
44	C gH 170 CH 26 CH 26 SF 4 OC 3F 8	95.5	79.9	-12.1		18.6	82.5
45	CaMero-Charles Cochicis Cochicis	93.8	82.2	-12.1		20.9	84.6
46	CoM170-CM2P CCM2P	104.4	96.4	-8		-0.2	98.7
48	CoHyO CH3Li OCH3CF3CC3F6	94.6	37	16.7			39
49	C ₀ H ₀ O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-	97.6	70.6	13.8		27.1	72.9
50	C4H40-CH2CF60C1F40C4F6	112.4	89.5	26.3		30	91.9
51	C ₂ H ₂ O—OH ₂ DCH ₂ CF ₂ OC ₂ F ₄ OC ₆ F ₁₉	100.7	80.6	20.6		42.9	83.2
52	C 3 M 3 TO C M 2 C F 3 (OC 3 F 4 b) CC F 3	101.4	68.6	-0.4		28.9	71
53	C,H1,O-O-1,F0C1F1	95.2	46.4	3.2		38.5	49.1
54	C,HHO CHOC,FACC,FA	88.9	5	4.7		31.3	
55	C ₂ H ₁₁ O-CH ₂ D-CH ₂ CF ₃ OC ₄ F ₁	87.6	32	-4.1		32.1	
56	C ₁ M ₁₁ O—OCM ₂ C ₂ F ₁ OC ₂ F ₄ OC ₄ F	112.1	89.3	43	0.7	7	91.5
57	C4M140-OCH2C2F40C4F	97.3	59.2	-7.5		33.7	61.6
58	C1H110-CH2h-CCH2CF3OC3F4OC1H1	101.3	80.4	15		49.8	82.5
59	C ₂ H ₁₃ —CCH ₂ L ₃ CCH ₂ CF ₃ CC ₃ F ₄ CC ₄	74.1	42.7	-8.1		4.9	45.2

Ex. No.	Structur	I to SA	to S _C	to S _{M1}	t K	to S _C	to S _A
60	C ₀ H ₁ yO-OCH ₂ CF ₃ OC ₃ F ₆ OC ₃ F ₆	101.5	70.3	-28		29.2	72.7
61	CONTROL CONTRO	107.3	76.6	-23.2		7.6	79.1
62	C4H12O————————————————————————————————————	93.6	55	-38.8		9.7	
63	CoMaso CH3CF3OC3F4OC4F6	105.8	81.2	-31.8		5	83.1
64	C ₄ M ₄₃ O————————————————————————————————————	116.4	97.9	42	-29	-22	100.2
65	C pH 1 20 C H 2 C 3F 4 OC 4 F 6	103.2	76.7	-38.5		-28.7	78.8
66	CgH1gO-CH2KFGOCgFGOCgH19	107.1	89.8	-24.2		23.7	92
67	C ₂ H ₁₁ —OCH ₂ CF ₂ (OC ₂ F ₄ O) ₂ OCF ₃	81	48	-23.9		3.3	50.2
68	C,H15—C)—(CH379—CH3CF30C3F40C4H13	81.6	60.9	-19.6		18.7	63.3
69	C;H150————————————————————————————————————	94.3	70.4	-22.5		-12.4	72.8
70	C,H150————————————————————————————————————	92.6	73	-23		14.8	75.4
71	CH460-CH204FeACCAFe	99.7	83.1	-19.9		-10.1	85.4
72	C ₂ H ₁₇ —CH ₂ h CH ₂ h CH ₂ h CH ₂ CF ₂ OC ₂ F ₄ OC ₃ F	74.8	56.2	<-30		9	58.7
73	C ₄ H ₁₃ O—OH ₂ CF ₃ OC ₄ F ₄ OC ₄ F ₁	105,8		-22.8			20.8
74	C ₀ H ₁₃ O	109.9		-5.9			18.3
75	C4H42O-CH2KF4OC4H41	108.3		6.3			39.9
76	C,Hts-CH325 CCH3CF3CC2F4CC4F	83.9		11.8			34.7

Ex. No.	Structure	I to SA	to Sc	to S _{MI}	to K	to S _C	to SA
77	C,Mar—CDN—(CH3)s CCH2C3F6OC4F6	86.7		17			34.9
78	C,H,,O—CO, CH,b CH,CF,(OC,F,b,OCF,	108.1		-7.3			29.2
79	C2M110-C1-10CH2CF2OC2F4OC2F4	103		-5.2			36.7
80	C ₁ M ₁ ₂ D———————————————————————————————————	107.9		-17.2			27.9
81	C7H15O-CH2C3F4OC4F6	101.5	88.1	-25.3		15.8	88.6
82	C 1H 110 CH 2K C 3F 0C 0F 0	102.3		-24.9			15.6
83	C 1HHO CHIC SF OC 4F 6	109.3		-9.8			24.3
84	С ₇ М _{1,7} ОСИ ₂ СБ ₇ ОСС ₇ Б ₄ ОСС ₆ М ₁₃	109-2	70.7	8.6		43.5	73.7
85	C ₀ M ₁₂ —COM ₂ CF ₃ (OC ₃ F ₄) ₂ OCF ₅	84		14			36
86	C ₉ M ₆ ———————————————————————————————————	78.1		17.8			44.3
87	CoHo CH2CF2OC2F4OC4F	83.2		14:5			36.8
88	C ₀ H ₁₇ —OCH ₂ C ₂ F ₄ OC ₄ F ₀	77.4		2.5			23.1
89	C ₀ H ₁₇ —OCH ₂ C ₂ F ₄ OC ₄ F ₆	76.7		-2.5			20.8
90	C ₀ M ₁ p————————————————————————————————————	86.3		25.7			49
91	C4M170-CH2CF1(OC2F4)20CF	110.3	66	-17.7		28.9	
92	C ₂ H ₁₇ O————————————————————————————————————	105.5	35	-5.3			35.4
93	C ₉ M ₁₇ O————————————————————————————————————	108.3	72	-18		29.2	

Er. No.	Structure	I to SA	to S _C	to S _{MI}	to K	to S _C	to SA
94	C ₀ M ₁ γO—ON ₂ M ₂ CF ₁ OC ₀ F ₀ OC ₀ F ₀	109.7	70	-17.3		28	
95	COMTO CHASE POCAFO	104.6	62.7	-14.8		21.5	65.7
96	CeH170-CH26 CCH26 DCH2C2F40C4F6	104.2	58	-15.1		20.5	
97	C _{ve} M _{ef} CCH ₂ b CCH ₁ CF ₁ OC ₂ F ₄ b ₇ OCF ₅	86.6	43.3	25.7			49.6
98	C_H_10-CH_2F_10C_2F_40C_4F_6	102.5		14			38.6
99	C ₀ H ₁₇ —Ch ₂ CF ₄ OC ₄ F ₆	79.7		22.6			43.8
100	C ₀ H ₁ yO— (CH ₂ h) COH ₂ CF ₃ (OC ₃ F ₄ hOCF ₃	107.7	45	11.2		39.2	
101	C+H1+O-O-F+OC+F-OC+F-OC+F-OC+F-OC+F-OC+F-OC+	106.7	80	9.4		37.8	
102	C,H,,O-CH,D; CCH,CF,OC,F,OC,F,OC,F	105.4		-34			9.4
103	C ₂ M ₁₂ O ₂ O ₂ F ₂ OC ₂ F ₃ OC ₄ F ₅	111.4	-3.3	<-30			8.5
104	C,H4,40	112.7	37	-15.6		23	
105	C,H,10-CH1CF1OC1F4OC3F1	109	38.8	-13.5		27.6	41
106	C,M150-CH20C1F40C4F4	109.9	77.1	-15		19	79.3
107	C7H15O-CH2CF4OC4F	105.9	50.6	-11.6		-6.1	53.6
108	C ₁ M ₁ /O————————————————————————————————————	113.5	72.1	-10.9		23.7	73.9
109	C ₀ M ₁₇ O-ON ₁ CF ₁ OC ₀ F ₀ OC ₃ F	109.7	70.6	-16.1		30.1	73.2
110	C gM 170-OH 200 4F	106.4	73.6	-7.1		-4.5	75.9
111	C ₀ M ₀ ,O—CH ₀ M ₀ CF ₀ (OC ₀ F ₀ M ₀ OCF	89.9	63.1	42.8		47.6	65.4

Ez. No.	Structure	I to SA	to S _C	t S _{M1}	to K	to S _C	to SA
112	C ₀ M ₁ ,O—O—O—OCH ₂ CF ₂ OC ₂ F ₃ OC ₄ F ₅	90.5	64.9	36.8		42.2	67.2
113	C ₄ H ₄ pO—OCH ₂ CF ₄ DOCF ₃	98	73.6	30.4		40.2	75.9
114	C ₉ M ₁₉ O-OCH ₂ De-OCH ₂ CF ₃ OC ₁ F ₄ OC ₁ F ₅	91.2	33	31.2			45.6
115	C ₀ M ₁ ,5D————————————————————————————————————	96.4	62.8	35.2		42.3	64.5
116	C _P M ₁₂ O—O—CH ₂ M ₂ CF _P OC ₂ F _e OC ₂ F _e	96.2	80.7	28.5		37.1	83.2
117	C ₁ H ₁₅ —CCH ₂ C ₃ F ₆ CC ₃ F ₇	75.3	46.5	28.4		35.2	48.2
118	C7H410-CH2h-CCH2CF3(OC7F4);OCF3	95	77.2	23.5		39.2	79.3
119	C,M1,0———————————————————————————————————	93.5	68	18.8		46.6	69.8
120	C1H180-C3F80C3F8	86	37	15.5		26.8	
121	C1H150-CH2CF50C2F5	94.8	61.5	31.1		38.6	60.9
122	Сэн ₁₆ О————————————————————————————————————	97.9	75.8	25.3		34.1	77.5
123	C,M+10-(CM2)2 CCM7CF10C1F6	88.1	57.3	22.5		41.4	59.9
124	C ₂ M ₁₇ —Ch ₂ h OCH ₂ CF ₂ loc ₂ F ₃ hOCF ₁	77.6	59.9	9.2		34	81.1
125	C ₀ H ₀ -CH ₂ h ₀ -CH ₂ CF ₂ OC ₂ F ₄ O	71.1	30	15.6			36.1
126	C ₀ H ₁ , CH ₂ h ₂ CCH ₂ C ₃ F ₀ CC ₃ F ₇	74.5	49.8	22		36	51.5
127	C ₂ M ₁₇ —CCH ₂ CF ₇ OC ₄ F ₈	64.5	26.4	21			32.6
128	C ₂ H ₁ , O-CH ₂ h CH ₂ h CCH ₂ CF ₁ OC ₂ F ₄ OC ₁ F ₅	97.9	85.1	8.9		37.7	87.4

Ex. No.	Structure	I to SA	to Sc	to S _{M1}	to K	to Sc	to SA
129	C ₆ H ₁ yo—OH ₂ C ₂ F ₆ OC ₂ F ₆	93	69.6	-3.5		30.4	71.3
130	C_H170-CH2C-F-0C2F3	97.9	85.1	8.9		37.7	87.4
131	C ₀ H ₁₇ O-CH ₂ C ₃ F ₀ OC ₃ F ₇	101.4	89.2	11.7		29.8	90.5
132	Cultura—CHale OCH 2CF30CaFa	92.7	79.3	6		20	81.5
133	C _p M ₁ ,ro—ON—OCM ₂ by—OCM ₂ CF ₂ OC ₁ F ₄ OC ₄ F ₆	103	93.7	12.9		32.9	95.6
134	CoH M CCH TCL TOC LE 10C LE 1	76.7	48	26.8	15.6	36.9	
135	C ₁ H ₁₈ —C ₂ H ₂ C ₃ F ₆ OC ₃ F ₇	80	60	23.5		41.4	64
136	C ₀ H ₁₀ ————————————————————————————————————	70.3	38	14.8		32.6	
137	C ₂ H ₁₀ OCH ₂ CF ₃ lOCF ₃ LOCF ₃	86.3	64.9	45.6		50.7	67.3
138	C ₂ H ₁₃ O————————————————————————————————————	94.3	67	35			40.4
139	C ₀ H ₁ , —OCH ₂ CF ₃ (OC ₂ F ₄) ₂ OCF,	77.6	59.9	9.2		34	81.1
140	C ₀ H ₁₉ O	88.3	79.2	15.4		37.5	80.4
141	C+H150-CH2N-CH2N-CF30C;F4	82.6		23,5			37.7
142	C#130-CH2C3F80C3F1	99.2	51	21.3		38.3	
143	C ₆ M ₁₃ O————————————————————————————————————	90	27	8.8			29
144	CaMin—Change Cochice focile	76.9	59.5	-5.7		14.5	62
145	C4M120-CH2CF20C4F40C4F8	100.2	82.5	9.1		18.9	84.8

Er No.	Structure	I to SA	to Sc	to S _{M1}	to K	to S _C	to S _A
146	C,H,170-OCH,2F,0C,F,0CF,	96	74				
147	Comino Conscrições de la Conscriçõe de l	106.1	95.6	-8.8		9.1	97.8
148	C ₉ H ₁₇ O————————————————————————————————————	88	61				
149	CaH 170-CH26 CH2C2FaOC4Fa	100.8	90.9	-8.2		13.6	93.4
150	C10H21-CH2h2-CCH2CF3OC3F4OCF3	64.80	59.1		19.3	25.1	61.6
151	C+H+10-CH+2h-CCH+CF+0C+F+0C+F+	96.3	68.7	-4.4	-	25.6	71.7
152	C ₀ H ₁₅ —OCH ₂ CF ₂ (OC ₂ F ₄) ₂ OCF ₃	75.2	32.3	-8.7		5.1	34.6
153	C ₂ M ₁₃ —CCH ₂ M ₂ CCH ₂ CF ₄ OC ₂ F ₄	67.9	19	-8.4		12.6	
154	C ₂ H ₁₃ O ₂ C ₃ F ₄ OCF ₃	96.1	40	-32		8.7	
155	C ₁ M ₁₂ O	106.1	83.2	-27.4		22.8	85.7
156	C4H110-CH2H2CH1CF10C1F40C1F7	102.1	79.2	-27.3		20.9	81.7
157	C,Hed—CH2P4 OCH2CF3OC3F4OC4F	78.4	55.2	-24.5		2.7	57.6
158	C ₀ M ₁ , — OCM ₂ CF ₃ (OC,F ₃) ₂ OCF ₃	79.00	57.5		-29.8	9.9	
159	C ₀ H ₁₇ —CH ₂ h—CCH ₂ CF ₂ OC ₂ F ₃	55.9	12	-24.5			16.4
160	C ₉ H ₄ , CH ₂ J ₉ CCH ₂ CF ₃ OC ₃ F ₄ OC ₃ F	72.00	47.6		-25	15.7	
161	C ₀ H ₁₇ —OCH ₂ CF ₃ OC ₂ F ₄ OC ₄ F	79.50	62.00	-25.40		-10.40	
162	C ₀ H ₁₇ —OCH ₂ L ₂ C ₂ F ₄ OC ₄ F	73.20	55.1		-29	25.4	

Ex. No.	Structure	I to SA	to Sc	to S _{M1}	to K	to Sc	to S _A
163	C+H110-C-10C4F40CF3	94.6	81.6	-16.7		-9.8	84
164	C.H.D. OCH,CF,IDCFF,IbOCFF	73.9		-22.9			28.9
165	C-H0-QQCH1/2-CH2-CC-F-CC-F-	71.8	35.3	-21.6		26.6	39.8
166	C ₀ M ₀ O————————————————————————————————————	91.6	57.6	12.6		20	60.3
167	C.M. 0	76.8	4	<-40			20
168	CoM1,10-CH214-CCH214-CCH2CF2CC1F4	74.7	40	-36.5	22.4	43.7	
169	CoMuso-Chara Control Palaces	84.4	56	<-35		-34.7	
170	C ₄ M ₁₂ O————————————————————————————————————	94.5	62.8	<-47			65.3
171	C ₂ M _{1,2} O————————————————————————————————————	76.7		<-47			
172	Called Conferences.	80.2	25	<-47			
173	Calling Conferences occise	82	63.5	-44.5		-32	65.8
174	C9H150-CH2C3F50C4F6	84.3	55.7	<-47		-35.5	58.2
175	C pH 130-C PF 15	83.1		-14.8			36.2
176	C,HLO-CH-LOCH, CF, OC., F, OC.	70.7	49.1	10.1		14.7	50.5
177	CqM110—COCHqCF20C2F40C4F6	73.8	50.1	-9.6		17	52.1
178	CaMaso OC Macrocoraccare	78.3		-40.2			5.7
179	C#4, 10 — CH1/2 OCH1/C,F,00C,F,	80.3		-35.9			6.4
180	C ₄ H _{1,3} O—OH ₂ CH ₂ H ₂ OCH ₂ CF ₃ OC ₄ F ₄ OC ₄ F ₆	83.1	69.8	<-40		0.7	71.2
181	C ₀ M ₁ yO—O—OCM ₂ C ₃ F ₀ OC ₄ F ₀	84.3	57.4	-34.5		6.8	59.8

Ex. No.	Structure	I to SA	to Sc	to S _{M1}	to K	to Sc	to S _A
182	C-May O-CHA LA ACCAP COCAP COC	86.3	73.7	-20.3		-12.6	75.9
183	C/Mago-Chack CF10CaF10CaF1	79.1	58	-23.3		6.6	
184	C,M, 10-CH,C,F,OC,F,	80.3	55	-24.7		7.8	58.6
185	Comito Comito Proces	78	70.4	-33		11.9	72.6
186	C_M, D	77.6	74	0.6	-11.2	3.2	77.3
187	Cartino-Cartinocas acces	73/71	54.4	8.7		15.6	56.6
188	CH-OCC-H-OC-P-IN CCF,	93.5	84.4	<-47		<-47	86.9
189	CHACCHIO-Q-CHIP CONTROL CONTROL SECONDO	61.9	54.4	16.3		21.8	56.5
190	CW-CCANO-Q-CCANOCANICCANICCANICCANICCANICCANICCANIC	55.2	47.2	8.2	-29.4	22.1	50.1
191	CHAOCHLO-CHAOCPADOCPADOCP	69.2	61.3	-22.2		-8.6	63.9
192	chiachiahanno-O-chricichantcharteriach	61.6	57	4.2		16.4	
193	CT TOTA LOT LOT LOT	32	24_	-14	<u> </u>	12.5	26.6
194	(CM) JOHCH 1,00-00, 10	69.6	63	<u> </u>	16.2	17.8	65
195	CH40C4M40	78.8	51.8	-19		10.5	55
196	CH40CH40	50	37.1		<5		
197	CHACANAO - CANADON CHONACON CONTACTAC	56.7	38.6	9.8	2.9	23.8	40.7
198	C*************************************	61.9	54.4	16.3		21.8	56.5
199	CHACHO - CH., COL, COCHOCHOCHOCHOCHOCHOCHOCHOCHOCHOCHOCHOCH	85.4	71.1	-0.9		10.1	73.1
200	CF3040C440	86.7	78.1	-5		22.7	80.4
201	C.F., CHLOC, H.O. — — — — — — — — — — — — — — — — — —	F	47.1	-2		13.3	
202	C4M170-OC2M40CH3CHCH2OCH2CF20C3F40C	108.9	93.6	19.9		39.2	

Ex. No.	Structure	I to SA	to S _C	to S _{M1}	to K	to S _C	to S _A
203	OH-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-	73		41.9			31.5
204	cro-Q-Q-a-a-lavarer	99.5	77.8	14.5		-1.6	80.3
205	CHATO-O-O-OCHORPOCHOCHOCH	129.7	80.4	-5		17.6	82.8
206	creo-Q}-Q	82	70.6	39.5		-30.8	73
207	CHIPO-O- DOUGHOCHOCH	81	68	⊲RT			
208		100.8	94.1	- 12.7		19.2	96.5
209		78.2	60.3	11.3		32.5	62.5
210	CH-Q-Q-Q-XXXXXXXXX	100.5	79.8	-0.6		11.7	82.3
211	CHO-Q-Q-Q-00100000000000000000000000000000	120.1	103. 1	-5.3		17.9	105. 9
212	CoH170-OC3H18CHCH20CH3CF20C3F40C4F8	100.9	75.5	2.2		24	78
213	C_H1,70-O-OC_SH10CHCH2CF2DC2F4DC4F8	111.5	94.2	-7.3		14.4	96.7
214	CAL_D	96.4	85.4	59.2		63.2	87.6
215	C.H.20-ON-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O-O	82	65	2			
216	C,M150-ON-OO-OO-F-0C1F-0C2F-0C2F-0C3F-0C4	68	48	-7			
217	C ₀ H ₁₉ O	93	81	24			
218	C*************************************	82.5	67.4	4			
219	CHI-90-CONCLEDGE CHECKER CONCLED CONCL	73.8	57.7	1.7			

The data in Table 1 shows that most of the compounds of the invention exhibit smectic mesophases

and that many of the compounds exhibit a broad smectic C mesophase, which makes the compounds well-suited for use in liquid crystal display devices. As a result of the breadth of the smectic C mesophase, the compounds are useful in admixture with themselves or with other liquid crystal compounds, even at high concentration.

The smectic C layer spacing of selected compounds of the invention was measured as a function of temperature by Small Angle X-ray Scattering (SAXS), essentially as described in U.S. Patent No. 5,417,883, and a plot of the data is shown in Figure 1. This data indicates that the compounds of the invention generally exhibited maintenance or expansion of the smectic C layer spacing with decreasing temperature (and can be used to control layer spacing with respect to temperature as described in U.S. Patent No. 5,417,883). The expansion rate varied with structure.

Examples 220 through 236

20 A series of devices, each containing a chiral compound of this invention (designated by a parenthetical reference to Example No. in Table 2 below), was prepared essentially as described in U.S. Patent No. 5,377,033 (Radcliffe). The ITO-constituted electrodes of each device were connected to an arbitrary waveform generator with variable output voltage. The device was driven by a voltage waveform consisting of bipolar, square pulses of $\pm 10V/\mu m$ amplitude, spaced 30 milliseconds apart by a train of square pulses having the same width and 3.3 $V/\mu m$ 30 amplitude. The device was heated to the temperatures noted in Table 3 (below) and the polarization (nC/cm²), the $\tau_{electric}$, the smectic viscosity, and the tilt angle ϕ_t were determined as described below:

The polarization of the device was determined essentially as described by Miyasato et al. in Jap. J. Appl. Phys. 22, 661 (1983). The electronic response time, τ_{electric}, was derived from the displacement current of the ferroelectric liquid crystal device under an applied square voltage pulse. The current was viewed on a 100 megahertz bandwidth oscilloscope. The usual decaying exponential, associated with a dielectric filled capacitor, was followed by the spontaneous polarization (P_S) switching pulse. The time from the rising edge of the voltage pulse to the peak of the P_S pulse was taken to be τ_{electric}. The rotational viscosity (smectic viscosity, η) was calculated as shown below:

15

20

 $\eta(10^{-3} \text{ kg / m} \cdot \text{s}) = 0.01 \cdot P_{\text{S}} \cdot \text{E} \cdot \text{'electric'}$ where the units of P_{S} , E, and τ_{electric} are respectively nC/cm²†, V/ μ m, and μ s. The tilt angle ϕ_{t} of the mixture was taken to be half the angle separating the extinction points of the driven states. The results given in Table 2 show fast response times over a wide temperature range.

Table 2.

Example No.	Temper- ature (°C)	Reduced Temper- ature (T-T _C , *C)	Polari- zation (nC/cm²)	Response Time (µs)	Smectic Viscosity (mPa·s)	Tilt Angle (degrees)
220	50.2	-9.3	25.3	5.8	14.6	22.6
(using	39.6	-19.9	31.6	7.0	22.0	24.1
compound	29.6	-29.9	37.1	8.1	29.9	24.6
of Ex.	19.5	-40.0	42.2	9.9	41.7	24.7
No. 144)	14.2	-45.3	45.0	11.2	50.4	24.7

		Reduced				
Example No.	Temp r-	Temper-	Polari-	Resp nse	Smectic	Tilt Angle
	ature (°C)	ature	zation	Time	Viscosity	(degrees)
		(T-T _C , *C)	(nC/cm²)	(µ s)	(mPa·s)	
221	40.5	-9.9	27.1	5.0	13.6	20.8
(using	30.3	-20.1	33.1	6.4	21.2	21.7
compound	20.1	-30.3	38.8	7.5	29.1	22.1
of Ex. No. 40)	9.9	-40.5	45.2	9.4	42.5	0.0
222	53.0	3.0	2.1	8.0	1.7	
(using	42.7	-7.3	3.7	37.9	14.0	16.1
compound	32.5	-17.5	3.8	76.5	29.1	18.1
of Ex. No.	22.1	-27.9	2.1			18.9
106)				<u> </u> 		
223	73.5	-8.5	27.5	5.2	14.4	23.3
(uzing	62.9	-19.1	34.6	6.1	21.0	24.9
compound	52.7	-29.3	41.2	7.0	28.6	25.6
of Ex.	42.7	-39.3	47.0	8.2	38.4	25.8
No. 45)	32.3	-49.7	53.3	10.3	54.8	25.9
	22.3	-59.7	59.3	13.4	79.6	25.7
	12.0	-70.1	61.2	19.5	119.6	25.5
224	87.6	-8.4	26.7	5.5	14.7	28.6
(using	77.5	-18.5	32.7	6.3	20.5	30.2
compound	67.2	-28.8	38.0	7.0	26.5	31.8
of Ex.	57.0	-39.0	42.6	8.0	33.9	32.0
No. 46)	46.8	-49.2	47.3	9.4	44.7	32.0
	36.5	-59.5	52.4	11.5	60.5	31.7
	26.2	-69.8	57.5	15.4	88.3	31.4
	16.0	-80.1	63.7	21.9	139.5	31.1
225	70.7	-1.3	6.4	6.2	4.0	15.3
(using	60.3	-11.7	9.7	10.5	10.2	18.0
compound	50.2	-21.8	11.7	13.1	15.2	18.8
of Ex.	40.1	-31.9	13.1	16.5	21.6	19.1
No. 93)	30.0	-42.0	14.2	22.1	31.4	19.1
226	91.6	-12.4	23.7	6.4	15.3	28.7
(using	78.0	-26.0	31.2	8.1	25.4	31.4

		Reduced				
Example No.	Temper-	Temper-	Polari-	Response	Smectic	Tilt Angle
	ature (°C)	ature	zation	Time	Viscosity	(degrees)
<u> </u>		(T-T _c , °C)	(nC/cm²)	(µs)	(mPa·s)	
compound	64.1	-39.9	38.5	10.6	40.9	32.6
of Ex.	50.1	-53.9	47.0	14.8	69.8	33.2
No. 73)	36.1	-67.9	58.1	22.6	131.4	33.6
	22.2	-81.8	72.6	39.9	289.4	33.9
227	85.6	-9.9	17.0	6.6	11.2	26.4
(using	75.8	-19.7	20.5	7.5	15.4	27.9
compound	65.6	-29.9	23.1	8.5	19.5	28.4
of Ex.	55.8	-39.7	25.2	9.7	24.5	28.4
No. 133)	45.6	-49.9	27.9	11.4	31.9	28.3
	35.6	-59.9	30.8	14.0	43.0	28.0
	25.5	-70.0	34.8	18.3	63.7	
228	69.1	-9.9	19.0	7.4	14.1	22.2
(using	58.9	-20.1	22.0	9.7	21.3	23.2
compound	49.0	-30.0	23.9	12.7	30.4	23.3
of Ex.	38.8	-40.2	25.6	17.3	44.3	22.9
No. 204)	29.1	-49.9	27.0	24.8	67.0	22.2
1	19.0	-60.0	28.5	42.0	119.7	21.4
	9.1	-69.9	30.1	77.2	232.4	20.6
229	55.3	-10.2	21.4	7.9	16.8	23.5
(using	45.4	-20.1	24.2	9.3	22.5	24.6
compound	35.5	-30.0	27.5	11.7	32.1	24.8
of Ex.	25.2	-40.3	30.0	15.8	47.4	24.7
No. 173)	15.2	-50.3	31.6	23.3	73.8	24.4
	5.4	-60.1	33.8	39.7	134.5	23.9
230	62.1	-10.1	21.7	8.8	19.0	27.4
(using	52.1	-20.1	27.9	10.2	28.3	29.1
compound	42.0	-30.2	34.6	12.1	41.8	29.8
of Ex.	32.1	-40.1	41.4	15.3	63.5	30.0
No. 206)	22.1	-50.1	49.2	20.5	100.9	30.1
	12.1	-60.1	56.2	30.2	169.8	30.0
	2.1	-70.1	65.4	51.8	338.6	29.8

		Reduced				
Example No.	Temper-	Temper-	Polari-	Response	Smectic	Tilt Angle
	ature (°C)	ature	zation	Time	Viscosity	(degrees)
		(T-T _c , °C)	(nC/cm²)	(µ s)	(mPa·s)	
231	72.1	-4.6	4.4	8.7	3.9	15.2
(using	67.2	-9.5	5.2	10.3	5.3	16.2
compound	56.8	-19.9	6.9	11.1	7.7	16.3
of Ex.	46.8	-29.9	8.1	12.1	9.8	16.1
No. 101)	36.7	-40.0	9.0	13.8	12.4	15.8
	26.7	-50.0	10.5	16.4	17.2	15.6
	16.6	-60.1	11.4	21.5	24.6	15.2
232	39.4	-9.9	74.3	11.5	85.6	35.3
(using	29.1	-20.2	89.8	16.4	147.2	37.1
compound	19.1	-30.2	98.3	25.6	251.5	37.9
of Ex.	9.1	-40.2	101.3	46.2	467.7	38.3
No. 216)	-1.0	-50.3	104.9	106.2	1114.0	38.4
233	39.3	-6.5	38.1	5.0	19.2	·
(using	32.2	-13.6	47.5	6.9	33.0	
compound	24.2	-21.6	58.2	8.7	50.6	
of Ex.	17.0	-28.8	69.3	10.6	73.7	
No. 59)	9.6	-36.2	82.2	14.0	115.1	
234	77.0	-11.5	38.2	4.6	17.8	
(using	66.8	-21.7	46.3	5.2	24.0	27.9
compound	56.8	-31.7	55.6	6.0	33.3	28.6
of Ex.	46.9	-41.6	61.1	7.0	42.7	28.8
No. 63)	36.9	-51.6	68.1	8.7	59.4	28.8
	26.8	-61.7	74.4	11.5	85.2	
	16.7	-71.8	80.1	16.4	131.2	
235	43.1	-7.1	42.7	4.2	17.9	
(using	38.4	-11.8	49.0	5.1	25.1	
compound	33.7	-16.5	55.5	6.0	33.6	
of Ex.	28.7	-21.5	62.8	7.1	44.4	
No. 53)	23.7	-26.5	70.0	8.3	57.8	
	18.8	-31.4	78.1	9.7	76.0	
	13.6	-36.6	88.4	11.5	101.8	

Example No.	Temper- ature (°C)	Reduced Temper- ature (T-T _C , *C)	Polari- zation (nC/cm²)	Response Time (μs)	Smectic Viscosity (mPa · s)	Tilt Angle (degrees)
236	68.0	-10.0	13.0	7.4	9.6	23.4
(using	58.0	-20.0	16.2	8.4	13.6	24.7
compound	48.0	-30.0	17.6	10.0	17.6	25.0
of Ex.	38.0	-40.0	19.1	12.6	24.1	24.9
No. 182)	28.0	-50.0	20.4	16.7	34.1	24.6
	18.0	-60.0	21.9	24.0	52.6	24.1
	8.0	-70.0	23.4	39.9	93.4	23.6

Example 237

A device was prepared essentially as described above using a mixture of 90 weight % of the compound of the invention prepared in Example 93 and 10 weight % 5-octyloxy-2-[4-(3-(4-

(nonafluorobutoxy)octafluorobutoxy)-2,2,3,3,4,4hexafluorobutoxy)2-(S)-fluoropropoxyphenyl]pyrimidine
(prepared essentially as described in Example 12 of

International Patent Publication No. WO 96/33251), and
the electrooptical properties of the mixture were
measured essentially as previously described. The
results are shown in Table 4.

15 Example 238 - 242

In the following Examples, a series of devices, each containing at least one chiral compound of this invention, were prepared essentially as described in U.S. Patent No. 5,377,033 (Radcliffe) and filled with a mixture of liquid crystal compounds. The composition of each mixture (in weight percent) and the phase transition temperatures of the mixtures are shown in Table 3.

quenched with water, and the resulting crude product was isolated by extraction with toluene and further purified essentially as in Example 1, followed by Kugelrohr distillation (187-92°C at 0.01 to 0.015 torr) to provide a yield of 4.45 g.

20 (trifluoromethoxy) tetrafluoroethoxy) 2,2-difluoroethoxy) hex-1-ene and 5-heptyloxy-2-(4(trifluoromethylsulfonyl) phenyl) pyrimidine.

Compound C, 5-heptyloxy-2-[4-(6-(3-(pentafluoroethoxy)-2,2,3,3-

25 tetrafluoropropoxy)hexyl)phenyl]pyrimidine was prepared
using essentially the procedure of Example 1 by
combining 3-(pentafluoroethoxy)-2,2,3,3tetrafluoropropoxy)hex-1-ene and 5-heptyloxy-2-(4(trifluoromethylsulfonyl)phenyl)pyrimidine.

30

5

10

Table 3.

		Example No.				
Compound	237	238	239	240	241	242
Example 93	90					
Example 12 of	10					

	Example No.					
Compound	237	238	239	240	241	242
WO 96/33251						
Example 155		15	15	10		
Example 63		30	30	20		
Example 211		25				
Example 30 of		10	10	10		
US 5658491						
Compound A		20	20	20		
Example 204			25			
Example 34				40		
Example 200					54	
Example 13					46	
Example 112						15
Example 44						20
Example 35						20
Example 151						10
Compound B						15
Compound C						20
Tran	sition	Tempe	rature I	Data (°C	:)	
I to SA	112.3	106.1	102.6	101.2	96.0	98.0
to Sc	55.4	74.0	68.2	64	79.2	55.4
to S _m	<6	<1	<1	<-1	10	<-5

Table 4.

Example No.	Temper- ature (°C)	Reduced Temper- ature (T-T _c , *C)	Polari- zation (nC/cm²)	Response Time (µs)	Smeetic Viscosity (mPa · s)	Tilt Angle (degrees)
237	46.6	-8.8	13.4	6.1	8.2	14.8
	36.7	-18.7	15.7	8.3	13.0	15.5
	26.8	-28.6	17.4	10.9	19.0	15.4
	16.5	-38.9	18.5	15.6	28.8	15.1
	6.4	-49.0	19.8	24.4	48.4	14.8

		Reduced				
Example	Temper-	Temper-	Polari-	Response	Smectic	Tilt Angle
No.	ature	ature	zation	Time	Viscosity	(degrees)
	୯୦	(T-T _c , °C)	(nC/cm²)	(μs)	(mPa·s)	
238	62	-10	22.5	6.1	13.7	23.3
	52	-20	27.7	7.3	20.2	24.9
	42	-30	31.9	9.0	28.7	25.6
	32	-40	36.2	11.4	41.1	25.9
	22	-50	40.7	15.9	64.5	26.0
239	58	-10	20.7	6.3	13.1	22.4
	48	-20	25.4	7.7	19.6	24.0
	38	-30	29.1	9.5	27.5	24.6
1	28	-40	32.6	12.1	39.4	24.8
	18	-50	35.7	17.7	63.1	24.8
240	52	-10	24.3	6.3	15.4	
	42	-20	28.8	7.4	21.5	
	32	-30	33.4	9.4	31.4	
	22	-40	37.1	12.8	47.5	
Ì	12	-50	41.8	18.7	78.2	
241	69	-10	33.7	6.9	23.1	29.0
	59	-20	41.7	8.0	33.3	30.9
	49	-30	48.5	9.6	46.6	31.8
	39	-40	57.0	12.0	68.3	32.3
	29	-50	64.9	15.7	102.2	32.5
	19	-60	76.3	22.2	169.2	32.7
242	49	-7	16.4	5.6	9.2	17.7
	38	-17	21.6	8.5	18.3	19.6
	28	-27	26.3	11.1	29.3	20.6
	23	-32	28.4	12.9	36.6	20.9
	18	-37	31.1	15.3	47.8	21.1
	8	-47	36.8	23.4	86.0	21.5

The results shown in Table 4 indicate that the compounds of the invention can be used in mixtures in liquid crystal display devices to provide low mixture viscosities and improve the performance of the devices.

Various modifications and alterations of this invention will become apparent to those skilled in the art without departing from the scope and spirit of this invention.

What Is Claimed Is:

- Fluorine-containing, chiral liquid crystal compounds having smectic mesophases or latent smectic 5 mesophases, the compounds comprising (a) a chiral fluorochemical terminal portion comprising (i) at least one chiral center, which can optionally be heteroatomsubstituted; (ii) a terminal fluoroalkyl, fluoroether, perfluoroalkyl, or perfluoroether group; and (iii) an alkylene or fluoroalkylene group optionally containing 10 at least one catenary ether oxygen atom; (b) a chiral or achiral terminal portion consisting of a hydrocarbon or hydrocarbon ether group and, when chiral, comprising at least one chiral center, which can optionally be 15 heteroatom-substituted; and (c) a central core connecting said terminal portions; said alkylene or fluoroalkylene group of said chiral fluorochemical terminal portion having at least 3 in-chain atoms and being located between said chiral center of said chiral fluorochemical terminal portion and said central core. 20
- The compounds of Claim 1 wherein said chiral fluorochemical terminal portion is represented by the formula -D-R*-D-R_f, where R* is a cyclic or acyclic chiral moiety containing at least one chiral center; R_f is fluoroalkyl, perfluoroalkyl, fluoroether, or perfluoroether; and each D is independently and non-directionally selected from the group consisting of a covalent bond,
- 30 $-C (=O) -O C_r H_{2r} -$, $-O C_r H_{2r} -$, $-O (O=) C C_r H_{2r} -$, -C = C -, -CH = CH -, -C (=O) -,
 - $-O(C_sH_{2s}O)_tC_rH_{2r}-$, $-C_rH_{2r}-$, $+C_sH_{2s}O)_tC_rH_{2r}-$, -O-, -S-,


$$-OSO_{2}-, -SO_{2}-, -SO_{2}-C_{r}H_{2r}-, -C_{r}H_{2r}-N-SO_{2}-, -N\left(C_{p}H_{2p+1}\right)-, \\ | \\ C_{p}H_{2p+1}$$

- 5 -C_rH_{2r}-N-C(=0)-, -CH=N-,
 and combinations thereof, where one or more hydrogen
 atoms can optionally be replaced with fluorine, and
 where r and r' are independently integers of 0 to about
 20, s is independently an integer of 1 to about 10 for
 each (C_sH_{2s}O), t is an integer of 1 to about 6, and p is
 an integer of 0 to about 4; with the proviso that there
 are at least 3 in-chain atoms between said central core
 and at least one said chiral center of R*.
- 15 3. The compounds of Claim 1 wherein said compounds are represented by the general formula (I):

$$R-(M)_{a}-A+(N)_{b}B+(P)_{c}-D-R*-D-R_{f}$$

$$\begin{vmatrix} & & | & & | \\ & & | & & | \\ & & X_{1} & Y_{m} & Z_{n} \end{vmatrix}$$
20

where M, N, and P are each independently selected from the group consisting of



5

a, b, and c are each independently zero or an integer
of from 1 to 3, with the proviso that the sum of a + b
+ c be at least 1;

10 each A and B are non-directionally and independently selected from the group consisting of a covalent bond,

$$-C(=0)-O-$$
, $-C(=0)-S-$, $-C(=0)-Se-$,

15 -C (=0)-Te-, $-(CH_2CH_2)_k-$ where k is 1 to 4, -CH=CH-, -C=C-, -CH=N-, $-CH_2-O-$, -C (=0)-, and -O-;

each X, Y, and Z are independently selected from the group consisting of -H, -Cl, -F, -Br, -I, -OH, -OCH₃, 20 -CH₃, -CF₃, -OCF₃, -CN, and -NO₂;

each 1, m, and n are independently zero or an integer
of 1 to 4;

- each D is non-directionally and independently selected from the group consisting of a covalent bond,

 -C(=O)-O-C_rH_{2r}-, -O-C_rH_{2r}-, -O-(O=)C-C_rH_{2r}-, -C≡C-,

 -CH=CH-, -C(=O)-,
- 30 $-O+C_sH_{2s}O+_tC_{r'}H_{2r'}-$, $-C_rH_{2r}-$, $+C_sH_{2s}O+_tC_{r'}H_{2r'}-$, -O-, -S-,

$$-OSO_{2}-, -SO_{2}-, -SO_{2}-C_{r}H_{2r}-, -C_{r}H_{2r}-N-SO_{2}-, -N\left(C_{p}H_{2p+1}\right)-, \\ | \\ C_{p}H_{2p+1}$$

where one or more hydrogen atoms can optionally be
replaced with fluorine, and where r and r' are
independently integers of 0 to about 20, s is
independently an integer of 1 to about 10 for each
(C₃H_{2s}O), t is an integer of 1 to about 6, and p is an
integer of 0 to about 4;

15 $\label{eq:Resolvent} \text{R is selected from the group consisting of } \\ -O-\left(\left(C_q\cdot H_{2q'-v}\cdot - (R')_{v'}\right) - O\right)_v - C_q H_{2q+1-v} - (R')_v \;, \\ -\left(\left(C_q\cdot H_{2q'-v'}\cdot - (R')_{v'}\right) - O\right)_v - C_q H_{2q+1-v} - (R')_v \;, \\ \end{aligned}$

20 -C (=0) -O-C_qH_{2q+1-v}-(R')_v, -O-(O=) C-C_qH_{2q+1-v}-(R')_v,

 $-CR'H-(D)_{q}-CR'H-C_{q}H_{2q+1-v}-(R')_{v}$,

30 where each R' is independently selected from the group consisting of -Cl, -F, -CF₃, -NO₂, -CN, -H, -C_qH_{2q+1},

 $-O-(O=)C-C_qH_{2q+1}$, $-C(=O)-O-C_qH_{2q+1}$, -Br, -OH, and $-OC_qH_{2q+1}$; q' is independently an integer of 1 to about 20 for each $(C_{q'}H_{2q'}-O)$; q is an integer of 1 to about 20; w is an integer of 0 to about 10; v is an integer of 0 to about 2; each v' is independently an integer of 0 to

about 2; g is an integer of 1 to about 3; each D is independently and non-directionally selected from the group set forth for D above, with the proviso that the ring containing D has from about 3 to about 10 ring atoms; each W is independently selected from the group consisting of N, CR', and SiR'; and R can be chiral or achiral; and

R* is a cyclic or acyclic chiral moiety containing at
10 least one chiral center; and

R_f is fluoroalkyl, perfluoroalkyl, fluoroether, or perfluoroether;

- with the proviso that there are at least 3 in-chain atoms between said central core structure $-(M)_a-A_{N}_bB_{P}_c-$ and at least one said chiral center of R*.

30 D

\ /

25

where each R' is independently selected from the group consisting of -Cl, -F, -CF₃, -NO₂, -CN, -H, -C_qH_{2q+1}, -O-(O=)C-C_qH_{2q+1}, -C(=0)-O-C_qH_{2q+1}, -Br, -OH, and -OC_qH_{2q+1}; q' is independently an integer of 1 to about 20 for

each (Cq'H2q'-0); q is an integer of 1 to about 20; w is
an integer of 0 to about 10; v is an integer of 0 to
about 3; each v' is independently an integer of 0 to
about 3; g is an integer of 1 to about 3; each D is
independently and non-directionally selected from the
group set forth for D in Claim 3, with the proviso that
the ring containing D has from about 3 to about 10 ring
atoms; each W is independently selected from the group
consisting of N, CR', and SiR'; and with the proviso
that R* is chiral.

5. The compounds of Claim 3 wherein said compounds are represented by the general formula (II):

15
$$R'' - (0)_{j} - G - D' - R^* - (C_{s'} H_{2s'} 0)_{t'} C_{r''} H_{2r''} - R_{f}$$
 (II)

where R'' is (R')_v-C_qH_{2q+1-v}, where q is an integer of 2 to about 10, each R' is independently selected from the group consisting of hydrogen, fluorine, chlorine,

20 methyl, and perfluoromethyl, and v is an integer of 1 to about 2;

- j is an integer of 0 or 1;
- 25 G is selected from the group consisting of

where one or more aromatic hydrogen atoms can be replaced with fluorine;

D' is selected from the group consisting of $-O(C_sH_{2s}O)_tC_r.H_{2r}-$, $-C_rH_{2r}-$, $+C_sH_{2s}O)_tC_r.H_{2r}-$, and $-O-C_rH_{2r}-$, where r and r' are independently integers of 0 to about 12, s is independently an integer of 1 to about 10 for each $(C_sH_{2s}O)$, and t is an integer of 1 to about 3;

 R^{\star} is selected from the group consisting of $-C_{q}H_{2q-v}-(R^{\star})_{\,v}-$ and

5

20

where R' is -F, q is an integer of 1 to about 4, v is an integer of 1 to about 3, W is N or CH, and D" is -C (=0) -O- or $-CH_2-$;

s' is an integer of 1 to about 6;

t' is an integer of 0 or 1;

5

r" is an integer of 1 to about 3; and

Rf is selected from the group consisting of $-C_qF_{2q+1}$ and $-(C_xF_{2x}O)_zC_yF_{2y+1}$, where q is an integer of 1 to about 6, x is independently an integer of 1 to about 10 for each $(C_xF_{2x}O)$, y is an integer of 1 to about 8, and z is an integer of 1 to about 5;

with the proviso that there are at least 3 in-chain atoms between said central core structure G and at least one said chiral center of R*.

Fluorine-containing, chiral liquid crystal compounds having smectic mesophases or latent smectic mesophases, the compounds comprising (a) a chiral fluorochemical terminal portion comprising (i) at least one chiral center, which can optionally be heteroatomsubstituted; (ii) a terminal perfluoroether group; and (iii) an alkylene group optionally containing at least one catenary ether oxygen atom; (b) a chiral or achiral 25 terminal portion consisting of a hydrocarbon or hydrocarbon ether group, and, when chiral, comprising at least one chiral center, which can optionally be heteroatom-substituted; and (c) a central core connecting said terminal portions; said alkylene group 30 of said chiral fluorochemical terminal portion having at least 3 in-chain atoms and being located between said chiral center of said chiral fluorochemical terminal portion and said central core.

7. Fluorine-containing, chiral liquid crystal compounds having smectic mesophases or latent smectic mesophases, the compounds comprising two fluorochemical terminal portions and being represented by the general formula VIII:

10

5

where n' is an integer of 0 to about 10; j is an integer of 0 or 1; each R, moiety is independently selected from the group consisting of fluoroalkyl, fluoroether, perfluoroalkyl, and perfluoroether; and all other moieties are as defined in Claim 3 above.

8. Chiral liquid crystal intermediate compounds represented by the following general formulas IV, VI, and VII:

20

15

$$B''+P+_c-D-R*-D-R_f \qquad (IV),$$

$$\begin{vmatrix} & & & \\$$

25

and

$$A''+N_{b}B+P_{c}-D-R^{*}-D-R_{f} \qquad (VI),$$

$$| \qquad | \qquad |$$

$$Y_{m} \qquad Z_{n}$$


30

where N, P, b, c, B, Y, Z, m, n, D, R*, and R_f are as defined in Claim 4; and A'' and B'' are selected from the group consisting of -H, -Cl, -Br, -I, -OH, -COOH, -CH(CH_2OH)₂, -SH, -SeH, -TeH, -NH₂, -COCl, -CHO,

35 -C=CH, dialkyl borane, -CH=CH₂, -OSO₂R_f''', -OSO₂CH₃, -OSO₂-cyclo(C₆H₄)-CH₃, -CH₂COOH,

-NH(C=0)OC $_q$ H $_2$ q+1 , -NCO, and -CH(C(0)O-C $_q$ H $_2$ q+1) $_2$, where R $_1$ ''' is a perfluoroalkyl group having from 1 to about 10 carbon atoms and q is an integer of 0 to about 20.

- 5 9. The compounds of any of Claims 1, 2, 3, 4, 7, or 8 wherein said R_f is perfluoroalkyl or perfluoroether.
- 10. The compounds of any of Claims 1, 2, 3, 4, 7, 10 or 8 wherein said $R_{\rm f}$ is perfluoroether.
- 11. A mixture of liquid crystal compounds comprising at least one fluorine-containing liquid crystal compound of any of Claims 1, 2, 3, 4, 5, 6, 7, 15 9, or 10.
 - 12. A liquid crystal display device containing at least one fluorine-containing liquid crystal compound of any of Claims 1, 2, 3, 4, 5, 6, 7, 9, or 10.



INTERNATIONAL SEARCH REPORT

int tional Application No PCT/US 98/14624

A. CLASSIF	COTD239/26 CO9K19/34	<u> </u>	
140 6	CU/U239/20 CU3K19/34		
	International Patent Classification(IPC) or to both national classification	on and IPC	
B. FIELDS :	SEARCHED cumentation searched (classification system followed by classification	symbols)	
IPC 6	C07D C09K		
Documentati	ion searched other than minimum documentation to the extent that suc	ch documents are included in the fields sea	rched
Electronic de	ata base consulted during the international search (name of data base	and, where practical, search terms used)	
CIOCATORIC GI	and seems and tackets and talk a series (seems as darkets) from the as agent asset		
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT		· · · · · · · · · · · · · · · · · · ·
Category *	Citation of document, with indication, where appropriate, of the relev	vant passages	Relevant to claim No.
,	ED O CCT 204 A COUNTTONO CUENTONI	(0)	1-3,5,9,
X	EP 0 667 384 A (SUMITOMO CHEMICAL 16 August 1995		11,12
	see claims 1,11,12; examples 22,2	8,34,55	
Y	WO 96 33251 A (MINNESOTA MINING &	MFG)	1-12
1	24 October 1996	- /	_
	cited in the application		
	see the whole document		
	-	/	
			·
-		Date of the state	ln annov
X Fun	ther documents are listed in the continuation of box C.	Y Patent family members are listed	NI MITHUM.
* Special c	ategories of cited documents :	T" later document published after the inte	
"A" docum	ent defining the general state of the art which is not dered to be of particular relevance	or priority date and not in conflict with cited to understand the principle or th invention	
	document but published on or after the international	"X" document of particular relevance; the cannot be considered novel or cannot	
T. docum	ent which may throw doubts on priority claim(s) or n is cited to establish the publicationdate of another	involve an inventive step when the de "Y" document of particular relevance; the	ocument is taken alone
citatio	on or other special reason (as specified) nent referring to an oral disclosure, use, exhibition or	cannot be considered to involve an in document is combined with one or m	ventive step when the
other	means nent published prior to the international filing date but	ments, such combination being obvious in the art.	
later	than the priority data claimed	"&" document member of the same patent	
Date of the	actual completion of theinternational search	Date of mailing of the international se-	
,	3 October 1998	2 2. 10.	1998
	mailing address of the ISA	Authorized officer	
Mame and	European Patent Office, P.B. 5818 Patentiaan 2		
	Nt 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo ni, Env. 431-70) 340-3016	Puetz, C	

1

INTERNATIONAL SEARCH REPORT

h .ational Application No PCT/US 98/14624

C.(Continue	INTO DOCUMENTS CONSIDERED TO BE RELEVANT	
Category •	and the mile work processor	Relevant to claim No.
Υ	NAGASHIMA Y ET AL: "THE SYNTHESIS AND MESOMORPHIC PROPERTIES OF FERROELECTRIC LIQUID CRYSTALS WITH A FLUORINATED ASYMMETRIC FRAME" LIQUID CRYSTALS, vol. 23, no. 4, October 1997, pages 537-546, XP000723914 see page 540, line 1 - page 541, left-hand column see tables 1,2 see scheme 1	1-12
A	EP 0 499 221 A (CANON KK) 19 August 1992 see page 7, line 1 - page 22, line 46 see examples	1,11,12
A	EP 0 434 297 A (SUMITOMO CHEMICAL CO) 26 June 1991 see claims 1-4	1
A	EP 0 301 511 A (CANON KK) 1 February 1989 see page 10, line 10 - page 22, line 7	1,11
i		
I		
	•	
		·

1

International application No.
PCT/US 98/14624

INTERNATIONAL SEARCH REPORT

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
2. X Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically: See FURTHER INFORMATION sheet PCT/ISA/210
Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box il Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This international Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

The ISA considers that the claims 1-12 fail to comply with the prescribed requirements of Article 6 PCT, namely that of support in the description , to such an extent that a meaningful search could not be carried out to cover the claimed subject-matter (cf. Article 17(2)(a)(ii) & (b) PCT). Said noncompliance with Article 6 PCT is considered to arise, due to the scope of said claims encompassing a vast number of possible solutions (compounds), whose number and scope is far greater than that which might reasonably be considered commensurate with the support provided by the examples - it includes a vast number of compounds structurally quite different and thus removed from the structure of said examples, even when taking into consideration a limited generalised structure o the latter. Consequently, the search has been directed to those parts (i.e. compounds) of the claims with are supported by specific examples in the description and/or by a generic structure derived from a limited generalisation thereof commensurate with the scope of of said specific examples (cf. Article 17(2)(b) PCT).

INTERNATIONAL SEARCH REPORT

Information on patent family members

In ational Application No PCT/US 98/14624

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
EP 0667384	A 16-08-199	16-08-1995	JP 7267885 A US 5779934 A	17-10-1995 14-07-1998	
WO 9633251	Α	24-10-1996	US CA EP	5702637 A 2217608 A 0821719 A	30-12-1997 24-10-1996 04-02-1998
EP 0499221	A	19-08-1992	US JP JP JP	5281362 A 1959193 C 5065276 A 6084357 B	25-01-1994 10-08-1995 19-03-1993 26-10-1994
EP 0434297	A	26-06-1991	DE DE US	69028905 D 69028905 T 5238598 A	21-11-1996 22-05-1997 24-08-1993
EP 0301511	A	01-02-1989	JP JP DE JP JP US	1242543 A 2510664 B 3867949 A 2000127 A 2660551 B 4918213 A 5073306 A	27-09-1989 26-06-1996 05-03-1992 05-01-1990 08-10-1997 17-04-1990